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Summary
Tobacco use is the leading preventable cause of death worldwide. In order to address 
this epidemic, it is important that we have a thorough understanding of the aetiology 
of tobacco use and dependence. Twin and adoption studies have consistently 
demonstrated the importance of genetic factors in smoking behaviours. The advent of 
genome-wide technologies has greatly facilitated the search to determine which 
specific genetic factors contribute to tobacco use phenotypes. A locus within the 
nicotinic acetylcholine receptor gene cluster CHRNA5-A3-B4 has generated 
particular interest – that marked by variants rs16969968 in CHRNA5 and rs1051730 
in CHRNA3. The primary aim of this thesis was to determine the role played by this 
locus in smoking-related behaviours, with an emphasis on phenotype refinement. A 
number of different approaches were utilised to address this objective, namely 
systematic review and meta-analysis, genetic epidemiology (including detailed 
phenotyping of smoking behaviour in adolescence), laboratory-based techniques, and 
genome-wide meta-analysis. Compelling evidence for a small, robust association was 
observed between the rs1051730/rs16966968 variants and daily cigarette 
consumption, equivalent to a per allele effect of approximately one cigarette per day. 
This effect was consistent across population sub-groups. Compelling evidence for an 
association between this locus and level of tobacco exposure was further illustrated 
through genome-wide meta-analysis of cotinine levels in current smokers. No 
association was observed between this locus and smoking initiation however, as 
examined in a prospectively assessed cohort using precisely defined phenotypes. An 
association between rs1051730/rs16969968 and smoking topography has yet to be 
explored. However, a full protocol was developed and piloted to investigate this. In 
addition, this research has also illustrated the importance of precise, objective, 
phenotype definition, an observation which has important implications for the fields 
of molecular genetics and epidemiology.
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Chapter 1 
Introduction 
1.1 Tobacco use: The current picture 
1.1.1 Prevalence and mortality 
 Tobacco use is one of the greatest public health concerns facing modern 
society. It currently accounts for the deaths of 5.4 million people a year – more than 
tuberculosis, HIV/AIDS and malaria combined (WHO, 2008). If current trends 
remain unchecked, it is estimated that tobacco use will account for the deaths of eight 
million individuals a year by 2030 (Mathers & Loncar, 2006). In order to address this 
growing epidemic, it is imperative that we have a thorough understanding of the 
aetiology of tobacco use and dependence.  
 
 “Tobacco is the only legally available consumer product which kills people 
 when it is used entirely as intended” 
(The Oxford Medical Companion, 1994, cited in WHO, 2008) 
 
 There are currently more than one billion smokers worldwide (WHO, 2008), 
approximately 10 million of which reside in Great Britain (ASH, 2012). In the UK, 
20% of the adult population are current smokers (21% of adult males; 20% of adult 
females) (ONS, 2012), who consume an average of 13.1 cigarettes per day (NHS, 
2011). Prevalence rates of smoking in the UK have been in decline since the peak 
noted in the late 1940s when official records began (65% adult males; 41% adult 
females) (NHS, 2011), although the rate of this decline has slowed dramatically in 
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recent years, with a mere 1% reduction in overall prevalence noted between 2007 
and 2010 (ONS, 2012). 
 Whilst figures suggest that tobacco use is now falling in high-income 
countries (albeit gradually), the epidemic has shifted to the developing world where 
tobacco use is increasing (WHO, 2008). This is of particular concern given the 
substantial time delay between the peak in smoking prevalence and the subsequent 
peak in smoking-related mortality (see Lopez, Collishaw, & Piha, 1994). 
1.1.2 Health consequences of tobacco use 
 Concerns regarding the potential health risks of tobacco use were raised as 
early as the late 18
th
 century, namely relating use of tobacco pipes to cancer of the lip 
(Sommering, 1795, cited in Doll, 1998). Throughout the late 1920s and 1930s further 
evidence emerged relating smoking to cancers of the lip, mouth and lung (Lickint, 
1929; Lombard & Doering, 1928; Muller, 1939), vascular disease (English, Willius, 
& Berkson, 1940) and decreased life expectancy (Pearl, 1938). In spite of this 
growing literature however, it wasn’t until the publication of two case-control studies 
in the 1950s documenting an association between smoking and lung cancer (Doll & 
Hill, 1950; Wyndor & Graham, 1950) that the negative health impact of smoking 
finally began to gain general recognition. Subsequent prospective cohort studies 
served to reinforce these findings, of which Doll & Hill’s classic study of the 
mortality of doctors in relation to their smoking habits remains a poignant example 
(Doll & Hill, 1954, 1956).  
 In 1962 the Royal College of Physicians (RCP) produced a report entitled 
‘Smoking and Health’ which concluded that smoking was an important cause of lung 
cancer, and associated with a variety of other diseases including chronic bronchitis, 
pulmonary tuberculosis and coronary heart disease. The comprehensive U.S. 
Chapter 1   Introduction 
3 
 
Surgeon General Report ‘Smoking and Health’ was published soon after in 1964 
(U.S. Department of Health, Education and Welfare, 1964).  
 In the Surgeon General’s 2004 report (U.S. Department of Health and Human 
Services, 2004), smoking was documented as a cause of cancers of the lung, larynx, 
oral cavity and pharynx, oesophagus, pancreas, bladder, kidney, cervix, stomach, and 
acute leukaemia. Smoking was also identified as a cause of multiple cardiovascular 
diseases (including coronary heart disease and stroke), numerous respiratory diseases 
(both acute (e.g., pneumonia) and chronic (e.g., chronic obstructive pulmonary 
disease)), fertility problems, and a broad spectrum of other diseases and disorders 
including loss of bone mass, dental diseases, erectile dysfunction and diseases of the 
eye. 
 Fifty years after the RCP publication of ‘Smoking and Health’, the list of 
diseases caused by smoking continues to expand. Smoking is now acknowledged to 
harm almost every organ in the body, and has been identified a risk factor for the six 
of the eight leading causes of death worldwide, namely ischemic heart disease, 
cerebro-vascular disease, lower respiratory infections, chronic obstructive pulmonary 
disease, tuberculosis and cancers of the trachea, bronchus and lung (WHO, 2008). 
The annual cost associated with treating smoking-related disease in the UK has been 
estimated at £5.2 billion (NHS, 2011). 
1.2 Neurobiology of tobacco dependence and the addictive potency of tobacco 
1.2.1 Introduction 
 In spite of a growing awareness of the negative health consequences of 
tobacco use, many continue to smoke. Whilst the majority of smokers express a 
desire to quit, they are unable to do so. A recent survey indicated that over 60% of 
smokers in the UK would like to stop smoking altogether (ONS, 2012). However, 
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only a minority of individuals (<5%) succeed in doing so without help in the long-
term (Cohen et al., 1989; Hughes et al., 1992). Tobacco is highly addictive. Here I 
discuss the pharmacology and addictive properties of nicotine (the primary 
psychoactive drug present in tobacco), alongside other factors and design features of 
tobacco products that may facilitate or promote dependence. 
1.2.2. Nicotine 
 Nicotine is the primary psychoactive drug present in tobacco. Although hotly 
disputed by the tobacco industry throughout the latter half of the 20
th
 century (see 
Henningfield, Rose, & Zeller, 2006), it is now clear that nicotine is an addictive drug, 
characterised by compulsive use, psychoactive effects, and drug-reinforced 
behaviour, and has been recognised as such by the World Health Organisation 
(WHO) and the US National Institute on Drug Abuse, and in the 1988 report of the 
US Surgeon General (Henningfield et al., 2006).  
 
 “The strength and persistence of self-administration of a drug is perhaps the 
 hallmark of its abuse liability, or ability to produce dependence” 
(Donny, Caggiula, Knopf, & Brown, 1995, p390) 
 
 The addictive properties of nicotine have been extensively evidenced in both 
the human and animal literature (for an excellent review see Le Foll & Goldberg, 
2009). Experimental paradigms for assessment include intravenous drug self-
administration, conditioned place preference, drug discrimination, and measurement 
of withdrawal disturbances (Le Foll & Goldberg, 2009). 
 Nicotine, at relatively low doses, is a stimulant. It increases heart rate and 
blood pressure, and has beneficial effects on cognition and performance. A recent 
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meta-analysis has evidenced its positive effects on attention, memory, and fine motor 
skills (Heishman, Kleykamp, & Singleton, 2010). Tolerance to nicotine can develop 
rapidly (within a few days of use), and cessation of use results in withdrawal 
symptoms, both somatic and affective, such as anxiety, restlessness, inability to 
concentrate, irritability, and change in appetite (Stolerman & Jarvis, 1995).  
 Nicotine exerts its pharmacological effects through binding to nicotinic 
acetylcholine receptors (nAChRs). These receptors are widely distributed throughout 
the central and peripheral nervous system. They are ligand gated ion channels 
composed of 5 transmembrane subunit proteins arranged around a central pore (see 
Figure 1.1). Neuronal nAChRs consist of α (α2-α10) and β (β2-β4) subunits (Gotti, 
Zoli, & Clementi, 2006), each of which is encoded for by a single gene (denoted with 
a ‘CHRN’ prefix), and may be homomeric or heteromeric in terms of subunit 
composition. Different combinations of subunits result in receptors differing in 
pharmacological and physiological profiles (Bierut, 2009; Paterson & Nordberg, 
2000). Individual subtypes differ, for example, in their affinity for nicotine, and 
sensitivity to upregulation and desensitisation following nicotine exposure (Paterson 
& Nordberg, 2000). Each receptor subtype has a distinct distribution profilewithin 
the brain (see Figure 1.2). The distribution of specific receptor subtypes within the 
brain has been determined through assessment of subunit mRNA using techniques 
such as in situ hybridisation, and also through imaging techniques such as PET and 
SPECT, using subtype selective radioligands (Paterson & Nordberg, 2000). The 
differential expression of specific subunits with distinct biological functions in brain 
regions mediating specific behaviours allows nicotine to exert a broad range of 
effects (Decker, Sullivan, Arneric, & Williams, 2000). The α4β2 receptor subtype is 
the most commonly expressed subtype in the human brain, and has historically been 
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implicated by animal models as critical to the experience of nicotine’s reinforcing 
effects (e.g., Picciotto et al., 1998). In recent years however, the importance of the 
role played by the lesser studied α3 and α5 receptor subunits in nicotine dependence 
has been recognised, as is discussed later at length. For a detailed description of the 
regional distribution of these subunits see Improgo, Scofield, Tapper, & Gardner 
(2010).  
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Figure 1.1. Structure of nicotinic acetylcholine receptors (figure reproduced from 
Changeux, 2010). 
 
[This image has been removed by the author for copyright reasons]
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Figure 1.2. Regional distribution of nicotinic acetylcholine receptors in the rodent 
central nervous system (figure reproduced from Gotti et al., 2006). 
 
[This image has been removed by the author for copyright reasons] 
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 Nicotine exerts its complex effects (arousal, mood modulation, pleasure) via 
several neurotransmitter pathways. Once bound to neuronal nAChRs, it facilitates the 
release of dopamine, serotonin, and a host of other neurotransmitters including 
GABA, glutamate, norepinephrine, acetylcholine and endorphins (Benowitz, 2008). 
The mesolimbic dopamine pathway has perhaps been the most widely studied in 
relation to nicotine dependence (Balfour, 2002). Dopamine release in the nucleus 
accumbens, resulting from nicotinic stimulation of dopaminergic neurons in the 
ventral tegmental area, is crucial to the processing of rewarding and reinforcing 
effects of nicotine. Indeed, dopamine release in the nucleus accumbens appears 
critical in the experience of rewarding effects of many drugs of abuse.  
 Chronic exposure to nicotine results in a number of neuroadaptions (Balfour, 
2002).  These include desensitisation of nAChRs, alongside an upregulation in their 
expression (Benowitz, 2008), factors linked to nicotine tolerance and withdrawal.  
 Continued pairing of the rewarding/reinforcing effects of nicotine with 
specific sensory and environmental stimuli (such as the smell of tobacco smoke, or 
the sight of a pack of cigarettes) results in these stimuli acquiring reinforcing 
properties.  These cues (conditioned reinforcers) have been linked to the maintenance 
of smoking, smoking-related cravings and relapse (Benowitz, 2008). 
 
1.2.3 Additional constituents and design features promoting dependence 
 Whilst nicotine is the key psychoactive drug found in tobacco, the addictive 
potency of cigarettes (and indeed other tobacco products) is likely influenced by 
product design and inclusion of a number of additives. Indeed, the addictive potency 
of cigarettes is higher than that of pure nicotine products (Henningfield & Zeller, 
2002). The modern cigarette is a sophisticated drug delivery device, carefully 
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tailored/engineered to optimise delivery of nicotine (and other constituents) to the 
smoker. The release of previously secret industry documents has evidenced this (see 
Hurt & Robertson, 1998). In this section we shall consider the role of tobacco smoke 
constituents, additives and design features of cigarettes that may facilitate/sustain 
tobacco dependence. 
 Sugars and polysaccharides are naturally present in tobacco, and commonly 
added to tobacco products in substantial quantities (SCENIHR, 2010). By 
themselves, these additives are not addictive, however, when burned they form 
numerous aldehydes e.g., formaldehyde and acetaldehyde. Acetaldehyde has not only 
been shown to have addictive potential in and of itself, as demonstrated through self-
administration experiments in animals (Philip Morris, 1992), but has also been 
shown to enhance the addictive potential of nicotine. Moreover, the interaction 
between these compounds was observed to result in a rewarding effect that exceeded 
the additive effects of both in rodent studies (Philip Morris, 1992). Study of the 
interactions between nicotine and other smoke constituents is crucial to our 
understanding of the addictiveness of cigarettes. 
 Monoamine oxidase (MAO) inhibitors are also present in tobacco smoke. 
MAO inhibitors increase levels of certain amines in the brain, such as dopamine and 
serotonin, and may subsequently potentiate the reinforcing effects of nicotine 
(Hatsukami et al., 2010). Indeed, animal studies have demonstrated that MAO 
inhibitors facilitate nicotine self-administration and enhance its motivational 
properties (Guillem et al., 2005; Villegier et al., 2006). Such findings may, in part, 
explain why cigarettes have much stronger reinforcing properties than pure nicotine.  
 Menthol and other flavourings (e.g., clove, liquorice) not only serve to 
increase the palatability of cigarette smoke, and, in the case of menthol and clove, 
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facilitate deeper inhalation and therefore higher nicotine dose (due to their 
cooling/local anaesthetic effects), but may also become conditioned reinforcers in 
themselves as a consequence of their repeated pairing with nicotine (Carter et al., 
2009). In addition, menthol also inhibits metabolism of nicotine to cotinine, 
purportedly through inhibition of CYP2A6 enzyme activity (Benowitz, Herrera, & 
Jacob, 2004), thus increasing the effect of nicotine. Cocoa and chocolate, which 
contain theobromine, are also common additives in tobacco. Theobromine is a 
bronchodilator, and thus has been proposed to enhance nicotine absorption in the 
lungs. However, theobromine content of cigarettes was deemed too low to exert 
bronchodilation in a recent review (SCENIHR, 2010).  
 Alkaline additives such as ammonia compounds are among the most 
abundant additives used in cigarette manufacture (Hurt & Robertson, 1998), added to 
cigarettes (and other tobacco products) in order to manipulate pH. Nicotine exists in 
both bound and unbound (“free”) forms, dependent on pH. Unbound forms, abundant 
in alkaline conditions, are more physiologically active than bound forms, able to 
cross biological membranes into the bloodstream with greater ease. Industry 
scientists have extensively investigated the potential of pH manipulation to optimise 
nicotine delivery, and have fully exploited methods to increase tobacco smoke pH in 
order to maximise nicotine “kick” (see Hurt & Robertson, 1998), and, perhaps, to 
determine region of nicotine absorption: It is of note that the high buffering capacity 
of the lung lining fluid may limit the impact of smoke pH on nicotine absorption in 
the lungs (SCENIHR, 2010). In contrast, absorption of nicotine across the oral 
mucosa is more dependent upon pH (of particular relevance to cigars).  
 A number of physical characteristics of cigarettes have been engineered to 
manipulate nicotine delivery, including cigarette dimensions, filtration, ventilation, 
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paper porosity, and tobacco shred size (Hurt & Robertson, 1998). Ventilation, for 
example, serves to manipulate nicotine, tar and carbon monoxide levels through 
dilution of tobacco smoke, and is achieved through the introduction of holes in both 
the filter and paper wrap (SCENIHR, 2010). Ventilation technology was utilised in 
the production of “light” or “low-tar” cigarettes, which were promoted by the 
tobacco industry as healthier alternatives to full-strength cigarettes. Such labels have 
proved misleading however. Whilst smoking machine assessments suggest that these 
cigarettes yield lower doses of nicotine, studies have demonstrated that smokers 
compensate (e.g., through deeper inhalation, increased number of puffs per cigarette 
and so on) when smoking these cigarettes in order to achieve the same dose of 
nicotine attained whilst smoking stronger brands (Strasser, Lerman, Sanborn, 
Pickworth, & Feldman, 2007). Ventilation is also purported to effect particle size of 
tobacco smoke aerosol, which may impact on nicotine absorption into the 
bloodstream, although evidence for this is unclear. 
1.3 Genetics and smoking behaviour 
1.3.1 Heritability 
 Heritability is a measure of the degree of phenotype variability in a 
population that is attributable to genetic variation. Twin and adoption studies have 
allowed us to determine the relative influences of genetic and environmental factors 
on smoking-related behaviours. These approaches are discussed in detail below. 
 Adoption studies: Adoption studies have allowed us to disentangle the 
influence of genetic and environmental factors as causes of family resemblance 
(Plomin, DeFries, McClearn, & McGuffin, 2008). Examination of the degree of 
resemblance between adopted individuals and their biological parents enables us to 
determine genetic effects, whilst examination of the resemblance between adoptees 
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and their adoptive parents allows us to determine familial environmental influences 
(Sullivan & Kendler, 1999). 
 Twin studies: Classical twin study designs have been used since the early 
1920s to estimate genetic influence on behaviours/traits (hereto referred to as 
phenotypes) (see Merriman, 1924). Monozygotic (MZ) twins are considered to be 
genetically identical (with minor exceptions such as individual de novo somatic 
mutations). In contrast, dizygotic (DZ) or “fraternal” twins share approximately 50% 
genetic similarity, as observed between full siblings. Presumably, all twin pairs 
growing up together share the same common environment. Comparison of the 
correlation of phenotypes within MZ twin pairs with those of DZ twin pairs allows 
us to determine the degree to which that phenotype is under genetic and 
environmental influence. Statistical modelling may be used to determine variation in 
liability to a phenotype attributable to separate genetic and environmental 
components.  
 Twin and adoption studies have provided consistent evidence that genetic 
factors contribute to the aetiology of cigarette smoking, playing an important role in 
smoking initiation, progression to heavy use and persistence (Fowler et al., 2007; 
Kendler et al., 1999; Lessov et al., 2004; Munafo & Johnstone, 2008; Sullivan & 
Kendler, 1999). A degree of variation in heritability estimates has been observed, as 
is to be expected given different time periods of assessment and different populations 
studied (Kaprio, 2009). For reference however, a recent meta-analysis (Li, Cheng, 
Ma, & Swan, 2003) reported that genetic factors were responsible for approximately 
50% of the variation noted in smoking initiation, and approximately 60% of variation 
in smoking persistence.  
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 As an aside, it is important to bear in mind that genetic and environmental 
factors do not always act as independent factors. Environmental factors can, for 
example, influence expression of genetic effects. Whilst the study of gene × 
environment (G×E) interactions in the context of behavioural phenotypes has proved 
controversial (Flint & Munafo, 2008; Riley, 2008; Uher, 2008), smoking is one case 
where there is a priori evidence of interaction – whatever one’s genetic risk, it is not 
possible to become tobacco dependent without first exposing oneself to tobacco. 
Environmental factors may plausibly influence the probability of tobacco 
experimentation, and thereby moderate the expression of genetic liability for 
subsequent dependence. These issues are discussed at length in Chapter 3.  
1.3.2 Molecular genetics 
Genetic epidemiological studies, primarily exploiting classical twin designs, 
have provided a wealth of evidence demonstrating the importance of genetic factors 
as a whole in the aetiology of smoking-related behaviours. Advances in the 
identification of specific genetic variants associated with such phenotypes are now 
being made in the field of molecular genetics. Multiple approaches have been utilised 
to identify specific genes and their relationship to specific smoking-related 
phenotypes, namely linkage analysis, candidate gene association studies and, more 
recently, genome-wide association (GWA) studies. These approaches are discussed 
below. 
“In genetic epidemiology, gene variation is not measured directly. Instead, 
the action of genetic and environmental factors is inferred from patterns of 
resemblance in special classes of relatives, particularly twins and adoptees. 
Molecular genetic studies relate disease risk directly to DNA variation”  
(Kendler et al., 2012, p.181). 
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 Linkage studies. Linkage studies employ a within-family design. This 
approach has traditionally been employed to study single-gene disorders, but may 
also be utilised to identify chromosomal regions associated with complex diseases 
such as smoking, for example through the study of sibling pairs (Dawn Teare & 
Barrett, 2005). Linkage studies of smoking-related phenotypes have identified a 
number of chromosomal regions, although regions identified using this approach 
have proven largely inconsistent across studies, and findings have not mapped well 
onto those stemming from candidate gene studies (David & Munafo, 2008).  
 Candidate gene association studies. This approach involves the comparison 
of allele frequencies between two groups of individuals at a pre-specified genetic 
locus. These groups are selected on the basis of a specific phenotype, and typically 
comprise a ‘case’ and a ‘control’ group (e.g., ever smokers versus never smokers), or 
groups displaying extremes of a trait (e.g., heavy smokers versus light smokers).  As 
a specific genetic variant has to be selected for study, this approach is hypothesis 
driven (in contrast to linkage and genome-wide association studies). Variants 
selected for this approach are of known function, or linked to variants of known 
function, and are selected for the study of a specific phenotype on this basis, hence 
the name ‘candidate gene’ study. Candidate gene studies of smoking behaviour have 
focused primarily on targets within relevant neurotransmitter pathways (e.g., 
dopamine pathway genes) and enzymes associated with nicotine metabolism (e.g., 
CYP2A6) (Munafo & Johnstone, 2008). This approach has certain limitations. 
Firstly, as highlighted, a priori hypotheses are required with regards to candidature. 
Secondly, given that effects of individual variants in complex diseases tend to be 
very small, very large sample sizes are required to detect them. This may underlie 
persistent failures to replicate. 
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 Genome-wide association studies. Genome-wide association studies adopt the 
same approach to sample selection and analysis as candidate gene studies (i.e., 
comparison of allelic frequencies between groups selected on the basis of 
phenotype). However, instead of focusing on a specific (or handful of) pre-specified 
locus (loci), microarrays (‘gene chips’) are used to systematically genotype hundreds 
of thousands of genetic polymorphisms across the genome. As such, and in contrast 
to candidate gene studies, they are strictly agnostic in their approach, requiring no a 
priori hypothesis. The advent of genome-wide technologies has greatly facilitated the 
search to determine which genetic variants contribute to specific diseases, including 
smoking behaviours (Furberg et al., 2010; Liu et al., 2010; Thorgeirsson et al., 2010), 
and have aided identification of variants which would perhaps not have been 
considered previously on the basis of biological function. 
 Whilst molecular genetics has certainly advanced our knowledge of the 
genetic underpinnings of smoking behaviour, we are still far from a full and 
comprehensive understanding. This area has been notoriously hampered by failures 
to replicate promising initial findings. One major exception to this rule however 
concerns a locus within the nicotinic receptor gene cluster CHRNA5-A3-B4. This is 
discussed at length in the following section.  
1.4 The nicotinic acetylcholine receptor gene cluster CHRNA5-A3-B4 
1.4.1 Background 
 Nicotinic acetylcholine receptors (nAChRs), to which nicotine binds, serve as 
the ‘gateways’ through which nicotine exerts its effects on the brain, as previously 
discussed. Recent years have witnessed a rapid growth in research focused on the 
nAChR gene cluster CHRNA5-A3-B4 on the long arm of chromosome 15 (15q24-
25.1), responsible for encoding three nAChR subunits (α5, α3, and β4). One locus 
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within this cluster has generated particular interest – that marked by the single 
nucleotide polymorphisms (SNPs) rs16969968 in CHRNA5 and rs1051730 in 
CHRNA3. These highly correlated SNPs, which at the time of writing have been 
broadly studied, are now firmly established predictors of multiple smoking-related 
behaviours and diseases, and form the focus of this thesis. Within this section we 
discuss the initial discovery of an association between these variants and smoking 
behaviour, the numerous phenotypes with which they have been subsequently 
associated (smoking-related behaviours, diseases, and cognitive phenotypes; see 
Tables 1.1, 1.2 and 1.3 respectively), and potential mechanisms purported to underlie 
such associations. Gene × environment interactions are also discussed, alongside 
issues relating to phenotype definition and measurement precision. 
   
 
 
C
h
ap
ter 1
 
C
h
ap
ter 1
 
In
tro
d
u
ctio
n
 
Table 1.1.  Smoking behaviours associated with rs1051730/rs16969968 
 
Author Year Original research 
or meta-analysis 
Phenotype/s 
associated with SNP/s 
 
Notes 
Xie 2011 Original ND Interaction noted between childhood adversity and rs16969968 genotype in predicting ND 
in males only (no interaction seen in females). No main effect of rs16969968 noted 
however.  
Breetvelt 2011 Original Smoking quantity Association noted between rs16969968 and CPD and heavy smoking (25+ cig/day). No 
association noted with cessation, lifetime smoking, or current smoking. 
Munafo 2011 Original Smoking cessation Weak evidence of an association between rs1051730 and short-term smoking cessation. 
No evidence of association at later follow-up. 
Timofeeva  2011 Original Cotinine; Lung cancer 
risk 
rs16969968 associated with circulating cotinine levels and lung cancer risk. 
Siedlinski 2011 Original Smoking quantity Nominally significant association noted between rs1051730 and lifetime average CPD, but 
not current CPD. Sample consisted of 4 cohorts of ever smokers with COPD. 
Marques-Vidal  2011 Original Smoking quantity; ND; 
Difficulty quitting 
(borderline) 
rs1051730 associated with heaviness of smoking (assessed using heaviness of smoking 
index), ND, and nominally associated with difficulty quitting (although this effect was no 
longer apparent after adjusting for nicotine dependence). No association found with 
willingness/attempt/preparation to quit. 
Wassenaar  2011 Original  Smoking quantity; ND;  
Lung cancer risk (sig. 
after adjustment for 
pack-years) 
rs1051730 associated with CPD, ND (FTND score), and lung cancer risk. 
Kaur-Knudsen  2011 Original Smoking quantity; 
Pack-years; Lung 
cancer; Bladder cancer; 
COPD. 
rs1051730 associated with lung cancer, bladder cancer and COPD after adjustment for 
smoking.  No association with ischemic heart disease or ischemic stroke. rs1051730 was 
associated with smoking quantity (g/day) and pack-years (cumulative tobacco 
consumption), but not with smoking status, age of initiation, age of cessation, or smoking 
duration. Very large sample (>10k). 
Hong  2011 Original Smoking severity; 
Schizophrenia 
rs16969968 associated with smoking severity (measured using FTND) in both smokers with 
schizophrenia and control smokers. This variant was not associated with smoking status 
however in either schizophrenia patients or controls. 
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Rodriguez  2011 Original Continued smoking 
following 
experimentation 
rs16969968 genotype, acting recessively, affects smoking (namely continued smoking in 
those who experiment) similarly in adolescents (13-15 years) and adults (18 years). 
Examination of ORs suggests slightly larger effect at 18 years.  No association noted 
between rs16969968 and ‘experimentation’ (assessed as current & past vs. never smokers) 
at either age. 
Lori  2011 Original ND; Cotinine level rs16969968 nominally associated with ND (FTND score) and cotinine level.  
 
Sorice  2011 Original Smoking quantity rs1051730 associated with smoking quantity in two of three Italian populations (differing in 
environment, history, and genetic structure). 
Sarginson  2011 Original Smoking quantity Pharmacogenetic study. rs16969968 and rs1051730 associated with baseline smoking 
quantity. No association noted between either SNP and baseline ND as assessed using the 
modified Fagerstrom Test of Nicotine Dependence (mFTQ). Neither SNP associated with 
abstinence, craving or withdrawal during treatment, although other SNPs in the 15q24 
region were. 
Ducci  2011 Original Heavy/regular smoking 
(in adolescence and 
adulthood) 
rs1051730 associated with heavy/regular smoking (non-smoker control groups), with 
similar effect of SNP noted at age 14 and 31 years. No association noted between 
rs1051730 and occasional/light smoking (non-smoker control groups) however at either 
age, suggesting that this SNP is not involved in initiation. 
Kim  2011 Original Emphysema (severity); 
ND 
rs1051730 (and rs8034191) associated with ND (FTND assessed). Both SNPs also associated 
with severity of emphysema, but only in former smokers, not current smokers. 
Winterer  2010 Original ND; Cognition rs1051730 and rs16969968 associated with ND and cognitive performance (cognitive 
domains from the WAIS-R, and n-back task performance). 
Johnson  2010 Original ND rs16969968 associated with ND. An interaction between rs16969968 genotype and peer 
smoking was noted in predicting ND risk. 
Saccone  2010 Meta-analysis Lung cancer; COPD 
(nominal); Smoking 
quantity 
rs16969968 associated with lung cancer and COPD (marginal), after adjusting for CPD. 
rs16969968 associated with CPD. 
De Ruyck 2010 Original ND (borderline) rs1051730 marginally associated with FTND score. No association noted between this SNP 
and smoking cessation (abstinence assessed 1 week, 1 month and 6 months after short-
term nicotine patch treatment) or withdrawal symptoms however. 
Grucza  2010 Original ND rs16969968 associated with ND. rs16969968 exhibited a larger effect in later-onset (post 
16 years) smokers (contrasts Weiss et al., 2008). 
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Thorgeirsson  2010 Meta-analysis Smoking quantity rs1051730 associated with CPD. 
 
Furberg  2010 Meta-analysis Smoking quantity rs1051730 associated with CPD. 
 
Liu  2010 Meta-analysis Smoking quantity rs1051730 associated with CPD. 
 
Lips  2010 Original Smoking quantity; Lung 
cancer; UADT cancer 
rs16969968 associated with CPD and heavy smoking. An association was also noted with 
lung cancer (effect virtually unchanged following adjustment for smoking), and earlier age 
of lung cancer onset. Association also noted with UADT cancers. NO association with 
smoking initiation or cessation.  
Chen, Johnson  2009 Original ND rs16969968 associated with ND. Risk for ND associated with rs16969968 modified by level 
of parental monitoring – risk increased significantly with the risk genotype of this SNP 
when combined with lowest quartile parental monitoring. 
Keskitalo  2009 Original Smoking quantity; 
Cotinine 
rs1051730 associated with both CPD and serum cotinine level. Notably, proportion of 
variance accounted for by rs1051730 was five times greater for cotinine relative to CPD 
(4.3% vs. 0.9%). 
Chen, Chen  2009 Original ND; Symptoms of 
alcohol abuse 
rs1051730 and rs16969968 associated with FTND score. Both SNPs were also associated 
with symptoms of alcohol abuse/dependence, but the associated alleles were the opposite 
of that of FTND. NO association noted with cannabis abuse/dependence. 
Saccone  2009 Original ND rs16969968 associated with ND in full sample, and in separate European American and 
African American subsamples.  
Freathy  2009 Original Smoking cessation; 
Smoking quantity 
rs1051730 associated with smoking quantity and reduced ability of women to quit smoking 
during pregnancy. 
Saccone  2009 Original ND rs16969968 and rs1051730 associated with ND. 
 
Caporaso  2009 Original Smoking quantity rs1051730 associated with CPD. 
 
Breitling  2009 Original  Neither rs1051730 nor rs16969968 associated with cessation in ever heavy (>20 CPD) 
smokers. 
Weiss  2008 Original ND severity 
(dependent on age of 
initiation) 
rs16969968 and rs1051730 associated with severity of ND among long-term smokers who 
began daily smoking before age 16, but not among those who began  daily smoking post 16 
years. 
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Le Marchand  2008 Original Urinary concentration 
of nicotine equivalents; 
Carcinogenic tobacco-
specific nitrosamine 
levels 
rs1051730 and rs16969968 are associated with smoke exposure, as determined using 
measures assessing urinary concentrations of nicotine and its metabolites. This association 
survives adjustments for CPD, leading authors to conclude that “simple adjustment for 
number of cigarettes per day is inadequate to control for smoking dose in studies 
examining the independent association of these variants with smoking-associated lung 
cancer”. 
Sherva 2008 Original Smoking status; First 
smoking experiences. 
rs16969968 associated with smoking status (i.e.,  ever [ ≥5 CPD for ≥ 5 years]  vs. never 
[<100 cigs consumed in lifetime]), and, in Caucasians, experiencing a pleasurable buzz 
during the first cigarette. 
Spitz  2008 Original CPD; FTND; age at 
onset of lung cancer 
No evidence of association between rs1051730 and lung cancer in never smokers. Partial 
sample overlap with Amos et al. Age at onset of lung cancer was modified by genotype (risk 
genotype = earlier age of onset). Highest risk for variant noted in lightest smokers.  No 
association between rs1051730 and bladder/renal cancer. 
Thorgeirsson  2008 Original Smoking quantity; ND; 
Lung cancer; 
Peripheral arterial 
disease 
rs1051730 associated with CPD, ND, lung cancer and peripheral arterial disease. 
Bierut 2008 Original Habitual smoking; 
nAChR function 
rs16969968 and rs1051730 associated with habitual smoking (case = 20+ CPD for 6mths+; 
control  = 100+ cigs consumed in lifetime or had smoked daily for 1mth+ but never 
consumed >10CPD). rs16969968 associated with nAChR A5 subunit function  (minor allele 
results in subunit less responsive to nicotine agonist ) but not expression. 
Saccone  2007 Original ND rs16969968 associated with ND in candidate gene study.  
 
 
CPD = cigarettes per day, ND = nicotine dependence; FTND = Fagerström Test for Nicotine Dependence; COPD = chronic obstructive pulmonary disease; 
SNP = single nucleotide polymorphism; UADT = upper aerodigestive tract; WAIS-R = Wechsler Adult Intelligence Scale (Revised). 
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Table 1.2.  Diseases associated with rs1051730/rs16969968 
 
Author Year Original research 
or meta-analysis 
Phenotype/s 
associated with SNP/s 
Notes 
Timofeeva  2011 Original Cotinine; Lung cancer 
risk 
rs16969968 associated with circulating cotinine levels and lung cancer risk. 
Jaworowska  2011 Original Lung cancer rs16969968 associated with lung cancer risk, but not  bladder or laryngeal cancer, in Polish 
population. 
Wassenaar  2011 Original  Smoking quantity; ND;  
Lung cancer risk (sig. 
after adjustment for 
pack-years) 
rs1051730 associated with CPD, ND (FTND score), and lung cancer risk. 
Xun  2011 Original  rs16969968 was not associated with survival time in a large cohort of lung cancer patients 
(regardless of whether cause of death was from lung cancer or not).  Stratified analyses 
suggested a role for rs16969968 in influencing survival time in never-smoking lung cancer 
patients (all-cause mortality, and lung-cancer specific mortality to a lesser extent) although 
this is possibly due to small sample of never smokers. Study based on cohort from Hung et 
al. 
Chen, Wu 2011 Original  rs1051730 was not associated with pancreatic cancer risk. NB: Controls matched for 
smoking behaviour. 
Kaur-Knudsen  2011 Original Smoking quantity; 
Pack-years; Lung 
cancer; Bladder cancer; 
COPD. 
rs1051730 associated with lung cancer, bladder cancer and COPD after adjustment for 
smoking.  No association with ischemic heart disease or ischemic stroke. rs1051730 was 
associated with smoking quantity (g/day) and pack-years (cumulative tobacco 
consumption), but not with smoking status, age of initiation, age of cessation, or smoking 
duration. Very large sample (>10k). 
Hong  2011 Original Smoking severity; 
Schizophrenia 
rs16969968 associated with schizophrenia in both Caucasian and African-American non-
smoker schizophrenia patients compared with control non-smokers. This variant was not 
associated with smoking status however in either patients or controls. 
Chen, Gorlov  2011 Original Tumor size at diagnosis  rs1051730 associated with larger tumor size at diagnosis (squamous cell carcinoma). 
Chen, Truong  2011 Original UADT cancers rs16969968 associated with UADT cancers in women (but not men). No evidence for a sex 
effect on relationship between rs16969968 and CPD. 
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Sakoda  2011 Original Lung cancer rs16969968 associated with lung cancer risk. Diet had little impact on this relationship. A 
stronger association was noted however in individuals diagnosed at <70yrs of age, and in 
those with a baseline smoking history of <40 pack/years. 
Gago-Dominguez  2011 Original Bladder cancer 
(borderline) 
Association noted between rs8034191 (highly correlated with rs1051730) and bladder 
cancer which persisted after adjustments for CPD and number of years smoking. Borderline 
association noted with rs1051730. 
Kim  2011 Original Emphysema (severity); 
ND 
rs1051730 and rs8034191 associated with severity of emphysema, but only in former 
smokers, not current smokers. 
Erlich  2010 Original Opioid dependence 
severity 
rs16969968 associated with opioid dependence severity. 
Amos  2010 Original Lung cancer rs1051730 and rs16969968 associated with lung cancer in African American sample. 
 
Saccone  2010 Meta-analysis Lung cancer; COPD 
(nominal); Smoking 
quantity 
rs16969968 associated with lung cancer and COPD (marginal), after adjusting for CPD. 
rs16969968 associated with CPD. 
Wang  2010 Original Lung cancer; COPD Evaluated the role of smoking behaviour (pack-years) and COPD (both alone and in 
combination) as mediators of the relationship between rs1051730 and lung cancer. Also 
examined the mediating effect of smoking behaviour on the relationship between 
rs1051730 and COPD. Concluded that rs1051730 is both directly and indirectly associated 
with lung cancer. Pack-years was shown to be a mediator, yet COPD was “a more 
significant mediator than pack years” (11.5% vs. 7.6%). rs1051730 was also associated with 
COPD (pack-years also shown to mediate this relationship). 
Truong  2010 Original Lung cancer rs16969968 associated with lung cancer in white ever smokers. This association was 
observed for all histology types (adenocarcinoma/squamous/large cell/small cell), and was 
stronger for those diagnosed at younger ages. No association noted in never smokers or 
Asians. Very large sample (12k cases, 15k controls). 
Hansen  2010 Original Lung cancer African American (AA) sample. A four SNP haplotype spanning CHRNA5 (including 
rs16969968) and CHRNA3 was associated with increased lung cancer risk. rs16969968 was 
not singularly associated with lung cancer (possibly due to low frequency of risk variant in 
AAs). rs1051730 was not associated with lung cancer risk. 
Lips  2010 Original Smoking quantity; Lung 
cancer; UADT cancer 
rs16969968 associated with lung cancer (effect virtually unchanged following adjustment 
for smoking), and earlier age of lung cancer onset. Association also noted with UADT 
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cancers. NO association with smoking initiation or cessation.  
Lambrechts  2010 Original Emphysema rs1051730 genotype associated with the presence and severity  of emphysema. This 
association was independent of pack-years smoking. 
Girard  2010 Original  rs1051730 was NOT associated with lung cancer risk in never smokers. 
 
Yang  2010 Original  No convincing evidence to suggest an association between rs16969968 and lung cancer. 
 
Pillai  2009 Original COPD; Lung function rs1051730 associated with COPD and lung function 
 
Chen, Chen  2009 Original ND; Symptoms of 
alcohol abuse 
rs1051730 and rs16969968 associated with FTND score. Both SNPs were also associated 
with symptoms of alcohol abuse/dependence, but the associated alleles were the opposite 
of that of FTND. No association noted with cannabis abuse/dependence. 
Schwartz  2009 Original Lung cancer rs1051730 associated with lung cancer risk in ever smoking African Americans (AAs) and 
whites. Associated risk increased following adjustment for CPD in ever smoking AAs, 
whereas risk estimate decreased (NS) after same adjustment in whites. No association 
noted with cancer in never smoking AAs or whites. CPD did not vary by rs105 genotype in 
AA sample. 
Wang  2009 Original Alcohol dependence rs1051730 was associated with alcohol dependence,  whilst rs16969968 was not. 
 
Shiraishi 2009 Original Lung cancer  Asian sample. rs16969968 and rs1051730 associated with lung cancer. Relationship 
observed for all histological types, and in both smokers and ‘non-smokers’ (latter group 
defined as never regular smokers). 
Grucza  2008 Original Cocaine dependence The minor (A) allele of rs16969968 protective for cocaine dependence (whilst also a risk 
factor for ND). Effect replicated in additional sample. 
Young  2008 Original COPD rs16969968 associated with COPD. Authors conclude that the association previously noted 
between this SNP and lung cancer could largely be explained through its relationship to 
COPD. 
Liu  2008 Original Lung cancer rs1051730 associated with lung cancer. 
 
Spitz  2008 Original CPD; FTND; age at 
onset of lung cancer 
No evidence of association between rs1051730 and lung cancer in never smokers. Partial 
sample overlap with Amos et al. Age at onset of lung cancer was modified by genotype (risk 
genotype = earlier age of onset). Highest risk for variant noted in lightest smokers.  No 
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association between rs1051730 and bladder/renal cancer. 
Amos  2008 Original Lung cancer rs1051730 associated with lung cancer. In Texas population, adjusting for pack-years did 
not alter relationship. In UK population, this adjustment slightly weakened relationship. 
Hung 2008 Original Lung cancer rs1051730 associated with lung cancer risk. rs16969968 also associated in 5 subsequent 
replication studies. Similar risk observed across all histological types. NO association 
observed between rs16969968 and head and neck cancers (including those of the oral 
cavity, larynx, oesophagus).  
Thorgeirsson  2008 Original Smoking quantity; ND; 
Lung cancer; 
Peripheral arterial 
disease 
rs1051730 associated with lung cancer and peripheral arterial disease. 
 
CPD = cigarettes per day, ND = nicotine dependence; FTND = Fagerström Test for Nicotine Dependence; COPD = chronic obstructive pulmonary disease; 
SNP = single nucleotide polymorphism; AA = African American; UADT = upper aerodigestive tract. 
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Table 1.3.  Other phenotypes associated with rs1051730/rs16969968 
 
Author Year Original research 
or meta-analysis 
Phenotype/s 
associated with SNP/s 
Notes 
Janes 2011 Original Smoking cue reactivity FMRI study. rs16969968 associated with smoking-related cue reactivity in areas related to 
memory and habitual behaviour (dorsal striatum and hippocampus). NB: absence of the A 
allele associated with increased reactivity. 
Winterer  2010 Original ND; Cognition rs1051730 and rs16969968 associated with ND and cognitive performance (cognitive 
domains from the WAIS-R, and n-back task performance). 
Etter  2009 Original Novelty seeking 
(marginal) 
Potential association between rs16969968 and the temperament trait novelty seeking, 
although finding not robust to correction for multiple testing. No association noted with 
smoking status or cotinine levels. 
 
FMRI = functional magnetic resonance imaging; ND = nicotine dependence; WAIS-R = Wechsler Adult Intelligence Scale (Revised). 
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1.4.2 Discovery of the association between rs16969968/rs1051730 and smoking  
 behaviours 
An association between rs16969968 in CHRNA5 and nicotine dependence 
(ND) was first reported in 2007 in a candidate gene study conducted by Saccone and 
colleagues (Saccone et al., 2007), with the minor A allele found to confer increased 
risk.  The following year, the same locus (tagged by rs1051730 in CHRNA3, a 
variant highly correlated with rs16969968) was also found to be associated with 
smoking quantity, this time identified in a GWA study conducted by Thorgeirsson 
and colleagues (Thorgeirsson et al., 2008). This study also demonstrated an 
association between rs1051730 and nicotine dependence and two smoking-related 
diseases, namely lung cancer and peripheral arterial disease. Notably, whilst the 
candidate gene study was published first, it was the GWA study that made much 
more of an impact. This may have been because CHRNA5 was not recognised as a 
particularly strong candidate at the time, given the then known neurobiology of 
tobacco dependence - more emphasis had been placed on genes encoding α4 and β2 
subunits which had been implicated by animal models as critical to the experience of 
nicotine’s reinforcing effects (e.g., Picciotto et al., 1998). In contrast, the GWA study 
did not require a strong prior hypothesis regarding gene selection, as this approach is 
inherently agnostic with respect to candidacy. Furthermore, the simultaneous 
demonstration of an association between this locus and two smoking-related diseases 
lent further authority to this finding. These initial studies were followed by a number 
of others documenting a range of associations between this locus and smoking-
related behaviours and diseases. 
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1.4.3 Phenotypes associated with rs16969968/rs1051730 
 Smoking behaviour. The 15q locus has primarily been associated with 
measures of heaviness of smoking, including ND and smoking quantity, although 
there is some evidence for other phenotypes.  
SNPs rs1051730 and rs16969968 have been repeatedly associated with ND, 
typically assessed using the Fagerström Test for Nicotine Dependence (FTND) (L. S. 
Chen et al., 2009; X. Chen et al., 2009; Grucza et al., 2010; Johnson et al., 2010; 
Saccone, Saccone et al., 2009; Saccone, Wang et al., 2009; Saccone et al., 2007; 
Thorgeirsson et al., 2008; Wassenaar et al., 2011; Winterer et al., 2010). The impact 
of this locus on ND (and other smoking-related phenotypes) may be modified by 
different factors. The relationship has, for instance, been shown to be modified by 
age of smoking onset, although with inconsistent findings. Grucza et al. (2010) found 
that SNP rs16969968 exhibited a larger effect  in late-onset smokers (post 16 years), 
whilst in contrast Weiss et al. (2008) noted an association between this locus and 
severity of nicotine dependence only in individuals who became regular smokers 
before the age of 16. Reasons underlying this disparity are unclear. A parsimonious 
explanation would be that these were chance findings. However, they do illustrate 
the potential importance of age of smoking onset, which is plausibly supported by 
research highlighting differential effects of nicotine exposure in adolescent and adult 
rats (e.g., Schochet, Kelley, & Landry, 2004).  
Another related issue to be considered concerns the impact of these SNPs at 
different ages.  Both Rodriguez et al. (2011) and Ducci et al. (2011) have sought to 
address this question, comparing the effects of this locus on smoking behaviour 
during adolescence and adulthood. Although phenotype definition and ages studied 
vary between these studies and are not directly comparable, both draw a similar 
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conclusion - the effect of this locus on smoking behaviour appears to be consistent 
during both adolescence and adulthood. Rodriguez et al. (2011) found that 
rs16969968 was associated with continued smoking in individuals who have 
experimented with tobacco, with similar effects noted at ages 13-15 years and at 18 
years. Ducci et al. (2011) found that rs1051730 was associated with regular/heavy 
smoking, again with similar effects noted at ages 14 and 31 years.   
Environmental factors have also been shown to impact upon the relationship 
between rs1051730/rs16969968 and smoking-related behaviours, such as parental 
monitoring (L. S. Chen et al., 2009), peer smoking (Johnson et al., 2010), and 
childhood adversity (Xie et al., 2011). This is discussed in more detail in Chapter 3. 
 Smoking quantity, typically assessed in terms of self-reported daily cigarette 
consumption, is also well established as a correlate of rs1051730 and rs16969968 
genotypes (Breetvelt et al., 2011; Caporaso et al., 2009; Freathy et al., 2009; Kaur-
Knudsen, Bojesen, Tybjaerg-Hansen, & Nordestgaard, 2011; Keskitalo et al., 2009; 
Lips et al., 2010; Marques-Vidal et al., 2011; Sarginson et al., 2011; Siedlinski et al., 
2011; Sorice et al., 2011; Thorgeirsson et al., 2008; Wassenaar et al., 2011). Further, 
several meta-analyses published during the course of my Ph.D. have consistently 
documented this relationship (Furberg et al., 2010; Liu et al., 2010; Thorgeirsson et 
al., 2010). Each copy of the minor (risk) allele appears to account for approximately 
one cigarette per day in terms of variance in smoking quantity (Furberg et al., 2010). 
Given the above, it is perhaps unsurprising that levels of cotinine (the primary 
metabolite of nicotine) have also been found to associate with rs1051730 and 
rs16969968 genotype (Keskitalo et al., 2009; Le Marchand et al., 2008; Timofeeva et 
al., 2011). What is interesting, however, is that the relationship between this locus 
and nicotine metabolite levels appears to be stronger than the relationship noted 
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between this locus and daily cigarette consumption. Keskitalo et al.(2009) for 
instance found that rs1051730 was associated with both daily cigarette consumption 
and circulating cotinine levels, but, critically, also noted that the proportion of 
variance accounted for by this SNP was nearly five times greater for cotinine relative 
to daily cigarette consumption. This is explored in detail in Chapter 4. 
Evidence for an association between rs1051730/rs16969968 and smoking 
cessation has been observed, although evidence for this relationship is weaker than 
that observed for ND and smoking quantity. Freathy et al. (2009) found an 
association between rs1051730 and reduced ability of women to quit smoking during 
pregnancy, an effect subsequently replicated by Thorgeirsson & Stefansson (2010). 
In further support, Munafò et al. (2011) found weak evidence of an association 
between rs1051730 and short-term cessation outcome in a combined analysis of two 
prospective clinical trial samples, although no evidence of association was noted at 
later follow-up. However, Breetvelt et al. (2011) and Lips et al. (2010) found no 
association between rs16969968 and smoking cessation, while Breitling et al. (2009) 
also failed to note an association between rs16969968 and rs1051730 and cessation, 
as assessed in ever heavy smokers (>20 cigs/day). In a similar vein, De Ruyck et al. 
(2010) found no association between rs1051730 and the presence of withdrawal 
symptoms or smoking cessation outcome following short-term nicotine patch 
treatment. Furthermore, Marques-Vidal et al. (2011) found no evidence for 
association between rs1051730 and willingness, attempt, or preparation to quit. 
It is unclear whether or not rs1051730/rs16969968 is associated with 
smoking initiation. Lips et al. (2010) and Kaur-Knudsen et al. (2011) found no 
association between this locus and smoking initiation. A recent twin study (Maes et 
al., 2011) suggested that this locus plays a much more prominent role in ND relative 
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to smoking initiation/experimentation. However, Sherva et al. (2008), found an 
association between rs16969968 and smoking status (regular smoker vs. never 
smoker). Of particular interest, they also found an association between rs16969968 
and positive first smoking experiences, specifically experience of a ‘pleasurable 
buzz’. This may mediate the association between this SNP and increased risk of 
regular smoking. Inconsistencies in the definition of the ‘initiation’ phenotype may 
have hampered progress in this area – for example, the genes influencing initial 
experimentation (i.e., first puff) may differ from those underlying progression from 
experimentation to regular use. This is discussed at length in Chapter 3. 
Cancer. Many diseases have been associated with SNPs rs16969968 and 
rs1051730, amongst which lung cancer is certainly the most frequently reported, and 
has been noted across a range of histology types (adenocarcinoma; squamous cell; 
large cell; small cell), and in European, Asian, and African American samples (Amos 
et al., 2010; Amos et al., 2008; Hung et al., 2008; Jaworowska et al., 2011; Kaur-
Knudsen et al., 2011; Lips et al., 2010; Liu et al., 2008; Saccone et al., 2010a; 
Sakoda et al., 2011; Schwartz, Cote, Wenzlaff, Land, & Amos, 2009; Shiraishi et al., 
2009; Spitz, Amos, Dong, Lin, & Wu, 2008; Timofeeva et al., 2011; Truong et al., 
2010; Wang et al., 2010; Wassenaar et al., 2011; although see Yang et al., 2010). 
There is considerable debate as to whether this association is direct or mediated via 
the variants’ association with smoking quantity. Briefly, the former (direct) argument 
is supported by studies demonstrating a relationship between this locus and cancer 
following adjustment for smoking quantity (e.g., Kaur-Knudsen et al., 2011; 
Wassenaar et al., 2011), whilst the latter (indirect) is supported by studies which fail 
to note an association between this locus and cancer in never smokers (e.g., Girard et 
al., 2010), and the inadequacy of self-reported smoking measures in capturing true 
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tobacco exposure (Munafo et al., 2012). This is discussed in detail in Chapter 4. 
Several lung cancer specific phenotypes have also been associated with this locus, 
age of cancer onset/diagnosis being most predominantly reported (Lips et al., 2010; 
Sakoda et al., 2011; Spitz et al., 2008; Truong et al., 2010)  – presence of the minor 
allele is consistently associated with earlier age of onset/diagnosis (although see 
Jaworowska et al., 2011). SNP rs1051730 has also been associated with larger 
tumour size at diagnosis for squamous cell carcinoma (X. Chen et al., 2011). 
However, it does not appear to be associated with survival time in lung cancer 
patients (Xun et al., 2011). Additional cancers linked to this locus include upper 
aerodigestive tract cancers (e.g., those of the oral cavity, larynx, oesophagus) (Lips et 
al., 2010), although this association has not been consistently shown (Hung et al., 
2008), and more recent work suggests that it may be limited to women only (D. Chen 
et al., 2011). Bladder cancer has also been associated with this locus (Gago-
Dominguez et al., 2011; Kaur-Knudsen et al., 2011), although, again, this finding has 
not been consistently shown (Jaworowska et al., 2011; Spitz et al., 2008). Finally, 
Chen et al. (2011) found no association between rs1051730 and pancreatic cancer 
risk. 
Alcohol and substance use. Alongside tobacco dependence, rs1051730 and 
rs16969968 have been linked to dependence upon other drugs of abuse, including 
opiates (Erlich et al., 2010), cocaine (Grucza et al., 2008), and alcohol (X. Chen et 
al., 2009; Wang et al., 2009). Erlich et al. (2010) found that the minor allele of 
rs16969968 was associated with opioid dependence severity, the same allele that has 
consistently been associated with ND. In contrast, Grucza et al. (2008) found this 
same minor allele to be protective for cocaine dependence. Similarly, Chen et al. 
(2009) found that the major alleles of rs16969968 and rs1051730 were associated 
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with symptoms of alcohol abuse/dependence, whilst simultaneously demonstrating 
an association between the minor alleles and ND. They found no evidence for an 
association between these variants and cannabis dependence. Whilst these opposing 
effects are intriguing, they are based on a very limited number of studies and 
therefore require replication. 
Other disease outcomes. Chronic obstructive pulmonary disease/emphysema, 
a common smoking-related disease, has also been associated with rs16969968 and 
rs1051730 (Kaur-Knudsen et al., 2011; Kim et al., 2011; Lambrechts et al., 2010; 
Pillai et al., 2009; Wang et al., 2010; Young et al., 2008). Arguments as to whether 
this association is direct or mediated via the association with smoking quantity are 
also common here. An association between this locus and cardiovascular disease has 
also been demonstrated. For instance, Thorgeirsson et al. (2008) observed an 
association between rs1051730 and peripheral arterial disease, also a known 
smoking-related disease. Finally, Hong et al. (2011) have demonstrated an 
association between rs16969968 and schizophrenia. 
Other non-disease outcomes. How do we explain the associations noted 
between SNP rs16969968/rs1051730 and smoking related behaviours? Several 
studies investigating associations between these variants and cognitive and 
personality related phenotypes offer some insight. Etter et al. (2009) found marginal 
evidence of an association between rs16969968 and novelty seeking. Individuals 
with the AA (ND risk) genotype had higher novelty seeking scores than individuals 
of GG or AG genotype, suggesting mediation by personality trait (of note, however, 
no association was observed with ND). Winterer et al. (2010) reported an association 
between both rs1051730 and rs16969968 and cognitive performance as assessed by 
the Wechsler-Adult-Intelligence Scale and an n-back task measure of executive 
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function. The alleles associated with lower cognitive performance were also those 
associated with increased risk for ND. Against a background of previous research 
highlighting the role of nicotine as a cognitive enhancer (Warburton, 1992), the 
authors postulate that this locus may indirectly increase a subject’s liability to ND as 
a result of cognitive augmentation by nicotine consumption. Indeed, the increased 
prevalence of smoking noted in samples of individuals with neurocognitive disorders 
(e.g., attention-deficit hyperactivity disorder) has been attributed to nicotine’s 
beneficial effect on cognitive performance (e.g., improving attention) (Sacco, 
Bannon, & George, 2004). It has also been proposed that genetic effects on smoking 
behaviours may be mediated in part by their effect on reactivity to smoking cues.  
Janes et al. (2011) found an association between rs16969968 and brain reactivity to 
smoking-related cues assessed by functional magnetic resonance imaging (fMRI). 
They found that women without the risk allele for ND showed greater reactivity to 
smoking cues in regions such as the hippocampus and dorsal striatum relative to 
women possessing this allele. The authors speculate that smokers without the ND 
risk allele may thus continue to smoke due to heightened cue reactivity. The results 
of this study are counter-intuitive in comparison to previous research. However, 
differences in nicotine dependence were controlled for when comparing smokers 
with and without the ND risk allele. Other studies have not done this when 
investigating the effects of this variant, which may partly explain these results. 
However, the sample size was small, which increases the possibility that statistically 
significant results may reflect false positives (Green et al., 2008), and so these results 
should be interpreted with particular caution until they have been replicated. 
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1.4.4 Determining linking mechanisms 
 The evidence linking variants rs1051730 and rs16969968 to smoking-related 
behaviours is, at the time of writing, compelling. What is less clear, however, is the 
fundamental mechanism linking the two. Exactly how do these polymorphisms exert 
their effect?  Let us first consider their functional significance. SNP rs1051730 in 
CHRNA3 is a coding, synonymous variant (http://genome.ucsc.edu/), i.e., a variant 
which does not result in an amino acid change in the subsequent protein, which is 
therefore unlikely to be of functional significance. This variant may act as a proxy or 
tag for a functional SNP however, which may underlie the observed associations. In 
contrast to rs1051730, rs16969968 in CHRNA5 is a missense mutation, resulting in 
an amino acid change (aspartate to asparagine) in the resultant α5 nAChR subunit 
protein. This variant is of definite functional significance – in vitro studies have 
demonstrated that α5 receptor complexes with the aspartic acid variant exhibit a 
twofold greater maximal response to a nicotine agonist compared to α5 receptor 
complexes containing the asparagine variant (i.e., the  risk variant robustly associated 
with ND) (Bierut et al., 2008). Building upon this foundation of research, Fowler et 
al. (2011) sought to establish the underlying mechanism through an elegant series of 
experiments involving α5 knockout mouse models (analogous to individuals with 
reduced α5 receptor function, i.e., carriers of the rs16969968 risk allele). They noted 
that knockout mice responded more vigorously than wild-type mice for nicotine 
infusions at high doses. Whilst wild-type mice appeared to titrate delivery of nicotine 
dose (through self-administration) to achieve a consistent, desired level, knockout 
mice did not, consuming greater amounts as dosage increased. This led the authors to 
propose that deficient α5 signalling attenuates the negative effects of nicotine that 
serve to limit its intake, a conclusion which fits well with human research (i.e., 
Chapter 1  Introduction 
36 
 
C
h
ap
ter 1
 
C
h
ap
ter 1
 
In
tro
d
u
ctio
n
 
smokers carrying the rs16969968 risk allele are likely to smoke more heavily than 
their counterparts without the risk allele). Furthermore, they also demonstrated that 
this effect could be ‘rescued’ in α5 knockout mice through injection of a lentivirus 
vector into the medial habenula (MHb), rescuing expression of α5 subunits in this 
region. The knockout mice did not appear to differ from wild-type mice in 
experience of the rewarding effects of nicotine, but the inhibitory effect of high 
nicotine doses on the activity of reward circuitries observed in wild-types appeared 
to have been largely abolished in knockout mice. This observation is complemented 
by a previous study by Jackson (2010), where the differential effects of nicotine dose 
on reward between α5 knockouts and wild-types was illustrated using a conditioned 
place preference task. Fowler et al. (2011) further determined that this effect 
appeared to be mediated via the pathway between the MHb and the interpeduncular 
nucleus (IPN, to which the MHb projects) through α5 containing nAChRs. 
Diminished IPN activity in response to nicotine was observed in knockouts, and 
additionally, disruption of IPN activity increased nicotine self-administration. In 
short, it appears that high doses of nicotine stimulate the MHb-IPN tract through 
nAChRs containing α5 subunits. This results in the relay of an inhibitory 
motivational signal serving to limit further drug intake. This pathway acts alongside 
the classic ‘reward’ pathway. 
1.5 Summary 
 Tobacco remains the leading preventable cause of death worldwide. In order 
to address this epidemic, it is important that we have a thorough understanding of the 
aetiology of tobacco use and dependence. Tobacco dependence is a complex disease. 
Both genetic and environmental factors contribute to its aetiology. This has been 
demonstrated by both twin and adoption studies. The advent of genome-wide 
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technologies has greatly facilitated the search to determine which specific genetic 
factors contribute to tobacco use phenotypes. A locus within the nAChR gene cluster 
CHRNA5-A3-B4 has generated particular interest – that marked by SNPs rs16969968 
in CHRNA5 and rs1051730 in CHRNA3. Research is now focused on determining 
exactly how these variants influence tobacco use phenotypes, and on identifying 
additional variants robustly associated with these phenotypes. 
1.6 Aims  
1.6.1 Overview 
 The primary aim of this thesis was to determine the role played by the 
CHRNA5-A3-B4 gene cluster in smoking-related behaviours, with an emphasis on 
phenotype refinement to aid understanding of the mechanisms underlying these 
associations. Multiple approaches have been utilised to address this objective, 
namely systematic review and meta-analysis, genetic epidemiology, and laboratory-
based techniques. A secondary objective was to identify additional genetic variants 
robustly associated with smoking-related phenotypes. The clinical utility of this line 
of research is to further our understanding of the genetic contribution of smoking-
related behaviours, which may ultimately enable us to improve and personalise 
smoking cessation treatments. This, in turn, may help to reduce the substantial health 
concern associated with tobacco use. 
1.6.2 Systematic review and meta-analysis (Chapter 2) 
 Through systematic review and meta-analysis, I sought to evaluate the 
strength of evidence for the association between rs1051730 (CHRNA3) and 
rs16969968 (CHRNA5) and heaviness of smoking, assessed in terms of daily 
cigarette consumption. Secondary aims were to determine which (if either) of the two 
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variants  provided a stronger genetic signal, test for the existence of small study bias, 
explore the impact of year of publication, and investigate the impact of ancestry and 
disease state as potential moderating variables. 
1.6.3 Genetic epidemiology (Chapter 3) 
Using data from a prospectively assessed cohort, I sought to determine the 
association between rs1051730 and smoking initiation, given somewhat conflicting 
evidence in the field regarding this relationship. Initiation was assessed both in terms 
of ‘ever use’ of cigarettes, and also in terms of initial smoking trajectories – a novel, 
sophisticated phenotype which captures the complexities of initial cigarette use, 
determined using repeated measures of smoking frequency. Given that this variant is 
located in a gene responsible for encoding the α3 nicotinic receptor subunit, I 
hypothesised that rs1051730 would not be associated with ever (i.e., very first) use of 
cigarettes, but may be associated with initial smoking trajectories, namely those 
capturing progression from initial exposure to tobacco through to regular use. I also 
sought to determine potential modification in the expression of these genetic effects 
by a well-established environmental risk factor for smoking initiation, namely 
parental monitoring. Given that this variable may plausibly influence the probability 
of exposure to tobacco/opportunities to smoke, I hypothesised that level of parental 
monitoring would moderate the expression of the predicted genetic effect. 
1.6.4 Laboratory-based techniques (Chapter 4) 
 Previous research denotes a much stronger association between rs1051730 
and cotinine level (a precise, objective assessment of tobacco exposure) relative to 
self-reported daily cigarette consumption. Moreover, this relationship appears robust 
to adjustments made for daily cigarette consumption (Munafo et al., 2012). This 
suggests that even among equal cigarette consumers, there is genetically influenced 
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variation in total tobacco exposure. Building upon this foundation of research, I 
sought to determine whether differences in smoking topography (i.e., how a cigarette 
is smoked) influence the relationship between rs1051730 and salivary cotinine 
level.A recall-by-genotype based approach was proposed to address this objective. 
1.6.5 Genome-wide meta-analysis (Chapter 5) 
 The primary objective of this project was to identify additional genetic 
variants robustly associated with heaviness of smoking, in this instance assessed in 
terms of cotinine level, which, as has previously been demonstrated, is a more 
precise and objective assessment of tobacco exposure relative to self-reported daily 
cigarette consumption, thus offering a ‘cleaner’ genetic signal, and maximising 
power to detect genetic effects. To this end, we created a consortium (‘Cotinine 
Consortium’) comprised of seven studies to conduct a genome-wide meta-analysis of 
this phenotype. Given that this approach is agnostic with respect to candidacy, no a 
priori hypotheses were required.
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Chapter 2 
Systematic review and meta-analysis: 
Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking 
 
2.1 Introduction 
2.1.1 Meta-analysis 
 Meta-analysis is a statistical technique which allows the results from two or 
more separate studies to be combined (Deeks, Higgins, & Altman, 2011). Particular 
strengths of meta-analyses include “an increase in power, an improvement in 
precision, the ability to answer questions not posed by individual studies, and the 
opportunity to settle controversies arising from conflicting claims” (Deeks et al., 
2011). In contrast to the classic narrative review, which is subjective and prone to 
bias and error, meta-analysis is based on rigorous systematic review methodology, 
allowing a more objective appraisal of research evidence (Egger & Smith, 1997).  
 Central to the systematic review (including meta-analysis) is clear and 
transparent methodology for both identifying relevant studies for inclusion, and 
extracting and analysing information from them (Kirkwood & Sterne, 2003). With 
regards to study inclusion for meta-analytic purposes, “completeness and 
combinability” of evidence is key (Egger, Smith, & Phillips, 1997).  
 One problem inherent to meta-analyses based solely on the published 
literature is that of publication bias (i.e., preferential publication of significant 
findings over null findings). Publication bias, more accurately described as “small 
study bias” - a term used to “describe a trend for the smaller studies in a meta-
analysis to show larger treatment effects” (Sterne, Gavaghan, & Egger, 2000) - can 
distort combined effect estimates. Effect size estimates from small studies tend to 
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vary widely. For an effect borne out of a small study to be significant, it will have to 
be very large. Non-significant small studies are unlikely to be published. Those that 
are significant are likely to feature very large effect sizes. As a consequence of the 
above, inclusion of such studies in meta-analyses is likely to skew the overall effect 
size estimate, leading to an over-estimate of said effect (Sterne et al., 2000). 
Fortunately, however, the presence of such bias can be formally tested and corrected 
for using statistical tests (Egger, Davey Smith, Schneider, & Minder, 1997). An 
additional cause of bias in meta-analysis is that resulting from poor study quality 
(Kirkwood & Sterne, 2003). Given the inherent difficulties in objective assessment 
of study quality, Egger, Smith et al. (1997) suggest the use of sensitivity analysis to 
examine the potential impact of study quality on results, over and above the finite 
exclusion of certain studies on the basis of a somewhat subjective assessment. 
 In calculating overall effect estimates, meta-analytical methods adopt a 
weighted approach, whereby the results from larger studies (with smaller standard 
errors) are given greater weighting than those from smaller studies (with larger 
standard errors). A “fixed effects” or “random effects” model is typically employed 
for calculating summary estimates in meta-analyses. Selection of the most 
appropriate model is dependent on the degree of heterogeneity observed between 
studies. This can be calculated using the I
2 
statistic (see Higgins, Thompson, Deeks, 
& Altman, 2003) 
 In addition to providing single, combined effect estimates summarising 
defined literatures, meta-analyses are also able to answer questions beyond those 
posed by their constituent studies. For instance, they allow examination of effect size 
variation between subgroups (e.g., groups defined by gender, age, ethnicity, and so 
on) (Egger & Smith, 1997).  
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2.1.2 The CHRNA5-A3-B4 gene cluster and heaviness of smoking 
As previously discussed, many original studies have documented an 
association between SNPs rs1051730 and rs16969968 in the CHRNA5-A3-B4 gene 
cluster and heaviness of smoking. An association between the rs16969968 variant 
and smoking quantity was also recently identified in a meta-analysis of primarily 
new, unpublished data (Saccone et al., 2010b). Moreover, three recent genome-wide 
meta-analyses have further highlighted an association between this locus and 
smoking quantity (Furberg et al., 2010; Liu et al., 2010; Thorgeirsson et al., 2010). 
The CHRNA5-A3-B4 cluster is clearly an established region for smoking 
behaviour. At the time of project conception, no study-level meta-analysis had been 
conducted to determine the strength of association between rs1051730 specifically 
and smoking quantity, to determine whether the strength of association between both 
variants and smoking quantity differed according to sample ancestry or disease 
status, or to assess small study bias. It is of note that typically only one of these two 
SNPs tends to be used in analyses in the wider literature for practical reasons. It is 
therefore of interest to determine whether they should continue to be used 
interchangeably. We sought to: 1) evaluate the strength of evidence for the 
association between the rs16969968 and rs1051730 SNPs and heaviness of smoking 
(both in pooled and independent analyses), as measured by daily cigarette 
consumption, using meta-analytic techniques to synthesise existing published data; 
2) explore which variant provides a stronger genetic signal; 3) test for the possibility 
that small study sample sizes may have biased findings; 4) explore the impact of year 
of publication; 5) investigate the impact of ancestry and disease state as potential 
moderating variables. 
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2.2 Methods 
2.2.1 Selection of studies for study inclusion 
Studies were included that reported data on the CHRNA5 polymorphism 
rs16969968 and/or the CHRNA3 polymorphism rs1051730 and smoking quantity. If 
data regarding smoking quantity were presented categorically, or were available but 
not reported by genotype, we contacted the authors to determine whether data in an 
appropriate format for inclusion were available. Three attempts were made to contact 
study authors. If these attempts did not result in the provision of data, the study was 
included but coded as ‘data not available’. Studies in any language, reporting data on 
samples of any ethnic origin were included, as were studies reporting data on either 
single-sex samples or samples including both males and females.  
Studies were excluded if no data on smoking quantity were available, neither 
of the SNPs of interest was investigated, or if extreme smoking quantity phenotypes 
had been selected for analysis. Reviews, letters to the editor and editorials were 
excluded if these did not present new or relevant data. Family based studies were 
also excluded, due to differences in analytical approach. Additionally, studies were 
excluded if an inappropriate study design was employed (e.g., DNA pooling). 
2.2.2 Search strategy 
 The search was performed in Scopus and PubMed. These databases were 
searched from the first date available in each database up to 12
th
 May 2010 using the 
following search terms: “CHRNA5 or CHRNA3 or CHRNB4”; “rs16969968 or 
rs1051730”; “smok* and 15q2*”. Once articles had been collected, references were 
hand searched for additional studies of interest. 
The titles and abstracts of studies identified by these search strategies were 
examined, and those clearly fitting the inclusion or exclusion criteria were retained or 
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excluded respectively. Of the remaining studies a more thorough examination of the 
full-text and supplementary material (if available) was required to determine 
retention or rejection. All duplications were deleted. Where studies reported 
previously published data we included data from only one of the publications, 
namely that reporting the largest sample. Ten per cent of all studies identified by the 
search strategy were additionally assessed for eligibility by a second reviewer (inter-
rater agreement > 90%). Disagreements between reviewers were resolved by mutual 
consent.  
2.2.3 Data extraction 
 For each study the following data were extracted: a) authors and year of 
publication, b) sample characteristics (ancestry; disease state), c) SNP(s) studied, and 
d) mean (M), standard deviation (SD) and sample size (N) for cigarettes per day by 
genotype. Genotype frequencies were used to calculate deviation from Hardy-
Weinberg equilibrium (HWE), i.e., deviation of population allele and genotype 
frequencies from a constant state of equilibrium. Deviations from HWE may be due 
to a number of factors such as population admixture/stratification, selection at a locus 
or inbreeding, but are most frequently due to genotyping error, which can greatly 
reduce the power of a genetic study (Leal, 2005; Sen & Burmeister, 2008). Ancestry 
was coded as European or ‘Other’, given the paucity of studies reporting data on 
non-European samples. To be coded as European, a sample had to be comprised of at 
least 95% European individuals.  
2.2.4 Data analyses 
 Given the high linkage disequilibrium between rs16969968 and rs1051730 
(European: r
2
 = 0.902, Japanese/Chinese: r
2
 = 1.000, African: r
2
 = unavailable; 
calculated using HapMap data in conjunction with SNAP 
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[http://www.broadinstitute.org/mpg/snap/ldsearchpw.php]), we initially conducted 
pooled analyses incorporating data from all samples, regardless of SNP studied, 
omitting one dataset if data on both SNPs had been collected for a sample. The 
standard additive model of genetic action was used for evaluation. Small study bias 
was assessed using the Egger test (Egger, Davey Smith et al., 1997) for both pooled 
and independent SNP analyses. The impact of year of publication on effect size 
estimate was also examined. Data were analysed within both a fixed- and random-
effects framework. Individual study effect sizes were pooled to generate a summary 
effect estimate and 95% CI, the significance of which was determined using a Z test. 
Stratified analyses by sample ancestry (European vs. Other) and disease state 
(control/population vs. disease/partial disease, e.g., lung cancer cases) were 
conducted to ascertain the potential moderating effects of these variables. We also 
explored which SNP provided a stronger genetic signal. The differences in pooled 
effect sizes were determined using a Z test. 
Between-study heterogeneity was examined using a chi-square test, and 
quantified through calculation of I² - the conventional bounds for low, medium and 
high heterogeneity based on the I² statistic being 25%, 50% and 75%, respectively. 
Data were analysed with Comprehensive Meta-Analysis Version 2 statistical 
software (Biostat, Englewood NJ). 
2.3 Results 
2.3.1 Study selection 
 The search of Scopus and PubMed databases provided 585 records. Two 
additional records were identified through other sources (hand-searching references 
of identified papers). After adjusting for duplications, 432 records remained. Of 
these, 325 were discarded because after reviewing the abstracts it appeared that these 
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papers clearly did not meet the required criteria. The full texts of the remaining 107 
studies were examined in detail (Figure 2.1). Of these, 37 were identified for 
inclusion in the meta-analysis (Tables 2.1 and 2.2).
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Figure 2.1. Flow diagram of study selection. 
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Table 2.1. Studies included in rs16969968 meta-analysis 
 
Study Year 
Cigarettes per Day 
HWE Ancestry 
Disease 
State 
Duplicate GG GA AA 
M SD N M SD N M SD N 
Baker (WI/UTAH) 2009 Data not available. Data also analysed elsewhere (Weiss et al., 2008)     
Breitling 2009 25.51 10.70 200 25.28 10.63 241 28.37 10.83 89 Yes European No Yes 
Broderick (Phase II cases)₁ 2009 20.80 13.20 861 21.60 13.30 1033 23.00 13.60 332 Yes European Yes Yes 
Broderick (Phase II controls)₁ 2009 18.20 12.60 423 18.50 10.40 391 18.60 10.70 93 Yes European No Yes 
Caporaso 2009 Data not available     
Chen (VAANX-ND) 2009 26.24 16.98 374 27.09 16.72 351 29.32 15.68 73 Yes European Yes Yes 
Chen (VAFTND) 2009 24.99 15.00 461 27.28 16.25 499 29.51 17.21 142 Yes European Yes Yes 
Etter 2009 26.70 19.20 62 23.60 10.90 117 21.90 10.50 32 Yes European No No 
Greenbaum₂ 2009 8.73 7.02 47 8.89 6.62 62 12.31 9.09 16 Yes Other No No 
Grucza (COGA, nonhabitual smokers) 2008 8.47 4.08 43 8.52 4.48 46 11.90 4.56 10 Yes European Yes No 
Grucza (COGA, habitual smokers) 2008 25.72 9.84 139 27.47 11.48 156 26.16 10.43 45 Yes European Yes No 
Grucza (FSCD, nonhabitual smokers) 2008 12.12 7.25 74 13.76 9.28 51 10.29 6.63 7 Yes European Yes No 
Grucza (FSCD, habitual smokers) 2008 21.64 8.00 61 20.11 6.58 54 24.47 9.26 19 Yes European Yes No 
Hung 2008 Data analysed elsewhere (Lips et al., 2009)    
Landi (CPSII)₃ 2009 9.21 12.45 60 9.86 14.48 71 11.56 16.30 17 Yes European Yes Yes 
Le Marchand (Hawaii) 2008 22.03 10.12 393 23.54 9.80 159 27.57 10.91 31 No Other No Yes 
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Le Marchand (UMN-1) 2008 24.00 5.65 41 27.50 7.85 48 25.50 8.64 10 Yes European No Yes 
Le Marchand (UMN-2)₄ 2008 19.90 8.20 80 21.60 8.95 47 22.60 5.32 21 No Other No Yes 
Lips (Central Europe) 2009 14.10 7.91 1503 14.30 10.81 1795 14.50 8.19 526 Yes European Yes No 
Lips (Toronto) 2009 17.50 13.17 151 16.60 12.32 180 19.20 13.35 50 Yes European Yes No 
Lips (EPIC) 2009 12.80 8.88 841 13.00 8.14 1018 13.60 8.63 353 Yes European Yes No 
Lips (Liverpool) 2009 14.30 10.57 429 14.90 11.25 402 16.80 11.72 109 Yes European Yes No 
Lips (Hunt/Tromso) 2009 9.60 4.97 148 10.90 5.28 167 11.60 5.95 42 Yes European Yes No 
Lips (ARCAGE) 2009 15.60 14.21 958 15.30 14.10 1194 16.00 11.27 339 Yes European Yes No 
Lips (Latin America) 2009 14.50 17.01 1112 15.30 16.04 817 17.80 12.86 176 Yes European Yes No 
Liu (GELCC, cancer cases and controls) 2008 Data not available     
Liu 2010 Data not available     
McKay 2008 Data analysed elsewhere (Lips et al., 2009)     
Pillai (Bergen Discovery, cases and 
controls) 
2009 Data not available     
Ray (Discovery) 2010 Data not available     
Sherva 2008 Data not available     
Shiraishi (cases) 2009 28.70 14.00 919 29.70 11.80 64 25.00 2.20 2 Yes Other Yes Yes 
Shiraishi (controls) 2009 20.00 12.20 349 27.50 10.20 11 15.00 NA 1 No Other No Yes 
TAG  2010 Data not available     
Thorgeirsson 2010 Data not available     
Weiss (Utah/WI/LHS) 2008 Data not available     
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Wu 2009 Data not available     
Yang 2010 Data not available     
Young (Lung cancer cases) 2008 19.53 10.51 157 19.59 8.42 180 19.47 7.87 64 Yes European Yes Yes 
Young (COPD cases) 2008 Data not available     
Young (control smokers) 2008 22.23 9.53 222 24.14 11.17 202 27.87 15.36 45 Yes European No Yes 
Young 2009 Data analysed elsewhere (Young et al., 2008)     
Zienolddiny (cases) 2009 14.84 9.63 112 14.26 7.94 186 15.77 9.20 59 Yes European Yes Yes 
Zienolddiny (controls) 2009 14.16 6.23 174 14.71 6.51 194 14.97 5.41 58 Yes European No Yes 
 
Disease state: no=population/control sample; yes=disease/partial disease sample. Duplicate: no=sample provided data for rs16969968 only 
and was included in pooled SNP analyses; yes=sample also provided data for rs1051730 and was excluded in pooled data analyses. 
₁  rs16969968 not genotyped in Phase I cases and controls. 
₂ These data are identical to rs1051730 data from Greenbaum et al. (2006). rs16969968 was not genotyped in Greenbaum et al. (2006) but 
was in Greenbaum et al. (2009). Authors suggested use of rs1051730 data for rs16969968 analysis given their complete correlation (R²=1) 
in their primary sample. 
₃ rs16969968 data not available for EAGLE, ATBC and PLCO samples. 
₄ Data from additional participants provided by authors. 
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Table 2.2. Studies included in rs1051730 meta-analysis. 
 
Study Year 
Cigarettes per Day 
HWE Ancestry 
Disease 
state 
Duplicate CC CT TT 
M SD N M SD N M SD N 
Amos (Texas Discovery, controls, current) 2008 23.00 12.20 207 23.70 11.50 221 24.40 11.00 52 Yes European No No 
Amos (Texas Discovery, controls, former) 2008 28.00 14.70 294 28.70 16.10 290 33.30 15.60 73 Yes European No No 
Amos (Texas Discovery, cases, current) 2008 27.80 13.20 194 28.40 11.70 262 30.40 14.60 95 Yes European Yes No 
Amos (Texas Discovery, cases, former) 2008 27.10 13.90 230 26.90 14.50 279 31.00 14.90 93 Yes European Yes No 
Amos (Texas Replication, controls, current) 2008 21.40 13.30 146 20.90 10.20 136 25.00 11.10 42 Yes European No No 
Amos (Texas Replication, controls, former) 2008 25.90 15.70 120 29.30 17.70 124 35.20 14.70 26 Yes European No No 
Amos (Texas Replication, cases, current) 2008 27.50 15.30 116 26.10 11.70 142 28.30 13.10 51 Yes European Yes No 
Amos (Texas Replication, cases, former) 2008 26.20 14.50 143 26.30 12.60 188 28.30 11.90 62 Yes European Yes No 
Amos (UK Replication, controls, current) 2008 16.90 8.40 159 18.20 8.60 157 15.50 8.90 34 Yes European No No 
Amos (UK Replication, controls, former) 2008 18.60 14.10 286 18.50 11.50 261 20.10 12.10 59 Yes European No No 
Amos (UK Replication, cases, current) 2008 22.60 10.70 174 22.00 11.80 280 23.60 10.20 97 Yes European Yes No 
Amos (UK Replication, cases, former) 2008 21.50 13.10 513 22.90 13.00 568 24.90 15.10 198 Yes European Yes No 
Baker (WI/UTAH) 2009 Data not available. Data also analysed elsewhere (Weiss et al., 2008)     
Breitling 2009 25.57 10.77 197 25.26 10.67 239 28.71 10.40 89 Yes European No No 
Broderick (Phase I cases)₁ 2009 19.00 14.80 709 21.30 14.10 913 23.20 14.90 330 Yes European Yes No 
Broderick (Phase II cases) 2009 20.80 13.10 859 21.60 13.40 1036 22.90 13.40 332 Yes European Yes No 
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Broderick (Phase II controls) 2009 18.20 12.60 423 18.50 10.40 391 18.60 10.70 93 Yes European No No 
Caporaso 2009 Data not available     
Chen (VAANX-ND) 2009 26.07 16.86 380 27.19 16.54 359 28.63 15.44 67 Yes European Yes No 
Chen (VAFTND) 2009 24.98 14.97 464 27.08 16.25 506 29.21 17.26 139 Yes European Yes No 
Conti 2008 Data not available     
Freathy (ALSPAC - third trimester data)₂ 2009 10.44 6.96 522 10.93 6.43 561 11.45 7.13 157 Yes European No No 
Greenbaum 2006 8.73 7.02 47 8.89 6.62 62 12.31 9.09 16 Yes Other No No 
Greenbaum 2009 Data analysed elsewhere (Greenbaum et al. 2006)     
Hung (IARC) 2008 Data analysed elsewhere (McKay et al., 2008; Lips et al., 2009)     
Keskitalo 2009 15.80 8.78 194 17.67 9.90 221 17.42 8.20 60 Yes European Yes No 
Lambrechts (LEUVEN) 2010 22.20 9.80 259 23.40 10.40 301 23.40 10.60 99 Yes European Yes No 
Lambrechts (COPACETIC) 2010 19.80 9.20 200 21.40 10.60 203 23.60 9.80 53 Yes European Yes No 
Landi (EAGLE) 2009 14.49 12.64 1295 15.43 12.51 1898 17.37 13.08 701 Yes European Yes No 
Landi (PLCO) 2009 17.83 14.84 1360 19.70 15.21 1501 20.94 16.01 415 Yes European Yes No 
Landi (ATBC) 2009 20.20 9.01 1210 21.17 8.69 1405 22.52 9.51 386 Yes European Yes No 
Landi (CPSII) 2009 15.69 14.85 542 16.89 15.77 626 18.96 16.25 202 Yes European Yes No 
Le Marchand (Hawaii) 2008 22.01 10.11 393 23.37 9.84 157 27.78 10.89 31 No Other No No 
Le Marchand (UMN-1) 2008 24.10 5.68 40 27.50 7.85 48 25.50 8.64 10 Yes European No No 
Le Marchand (UMN-2)₃ 2008 19.90 9.04 79 21.60 8.52 48 22.60 8.17 21 No Other No No 
Liu (GELCC, cancer cases and controls) 2008 Data not available     
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Liu 2010 Data not available     
McKay 2008 Data not available     
Pillai 2009 Data not available     
Ray (Discovery) 2010 Data not available     
Rigbi 2008 Data analysed previously (Greenbaum et al. 2006)     
Schwartz (EA controls) 2009 17.11 10.36 177 18.89 10.81 168 18.54 9.69 52 Yes European No No 
Schwartz (EA cases)₄ 2009 25.71 11.25 190 28.31 13.74 273 29.29 13.67 86 Yes European Yes No 
Schwartz (AA controls) 2009 14.90 11.13 194 14.28 9.19 39 5.67 4.16 3 Yes Other No No 
Schwartz (AA cases)₄ 2009 16.66 10.77 267 20.31 11.90 96 22.50 8.64 8 Yes Other Yes No 
Shiraishi (cases) 2009 28.70 14.00 922 29.70 11.80 61 25.00 2.20 2 Yes Other Yes No 
Shiraishi (controls) 2009 20.20 12.30 350 25.20 10.20 10 15.00 NA 1 No Other No No 
Spitz (Bladder cancer cases)₅ 2008 37.58 29.42 299 45.17 30.38 314 48.14 30.10 81 Yes European Yes No 
Spitz (Bladder controls) 2008 29.78 30.37 224 30.37 26.30 198 38.44 27.60 57 Yes European No No 
Spitz (Renal cancer cases) 2008 29.72 27.59 72 29.12 21.66 63 19.04 12.78 7 Yes European Yes No 
Spitz (Renal controls) 2008 34.56 31.88 82 30.14 31.10 61 41.35 35.51 15 Yes European No No 
TAG 2010 Data not available     
Thorgeirsson (Iceland/Spain/Netherlands) 2008 Data not available     
Thorgeirsson 2010 Data not available     
Weiss (Utah/WI/LHS) 2008 Data not available     
Wu 2009 Data not available     
   
54 
 
 
C
h
ap
ter 2
                                                                                                            M
eta-an
aly
sis    
Young (Lung cancer cases) 2008 19.53 10.51 157 19.59 8.42 180 19.47 7.87 64 Yes European Yes No 
Young (COPD cases) 2008 21.09 8.86 161 23.20 11.05 204 24.44 13.97 54 Yes European Yes No 
Young (control smokers) 2008 22.23 9.53 222 24.14 11.17 202 27.87 15.36 45 Yes European No No 
Zienolddiny (cases) 2009 14.66 9.55 110 14.19 8.03 184 16.15 9.08 58 Yes European Yes No 
Zienolddiny (controls) 2009 14.13 6.28 174 14.78 6.47 195 15.05 5.47 56 Yes European No No 
 
Disease state: no=population/control sample; yes=disease/partial disease sample. 
₁ rs1051730 not genotyped for Phase I controls. 
₂ All EFSOCH and ALSPAC lifetime, pre-pregnancy and first-trimester CPD data available in categorical format only. CPD data available in 
continuous format for ALSPAC third-trimester only (displayed). 
₃ Data from additional participants provided by authors. 
₄ Data from all histology cases included, not just NSCLC cases as displayed in paper. 
₅ Texas discovery and replication samples excluded as analysed previously in Amos et al. (2008). Never-smoking lung cancer cases and controls also 
excluded. 
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2.3.2 Characteristics of included studies 
 A total of 37 studies published between 2006 and 2010 were identified for 
inclusion in the meta-analysis. Of these, 19 studies (comprising k = 57 independent 
samples, and a further k = 15 duplicate samples) provided data contributing to the 
meta-analysis (Amos et al., 2008; Breitling et al., 2009; Broderick et al., 2009; X. 
Chen et al., 2009; Etter et al., 2009; Freathy et al., 2009; Greenbaum et al., 2006; 
Greenbaum, Rigbi, Teltsh, & Lerer, 2009; Grucza et al., 2008; Keskitalo et al., 2009; 
Lambrechts et al., 2010; Landi et al., 2009; Le Marchand et al., 2008; Lips et al., 
2009; Schwartz et al., 2009; Shiraishi et al., 2009; Spitz et al., 2008; Young et al., 
2008; Zienolddiny et al., 2009). The remaining 18 studies identified for inclusion did 
not contribute data, as data from these studies were not available or the sample(s) 
featured had been included in another study which we had already included in our 
analyses (refer to Tables 2.1 and 2.2) (Baker et al., 2009; Caporaso et al., 2009; Conti 
et al., 2008; Tobacco and Genetics Consortium, 2010; Hung et al., 2008; Liu et al., 
2010; Liu et al., 2008; McKay et al., 2008; Pillai et al., 2009; Ray et al., 2010; Rigbi 
et al., 2008; Sherva et al., 2008; Thorgeirsson et al., 2008; Thorgeirsson et al., 2010; 
Weiss et al., 2008; Wu et al., 2009; Yang et al., 2010; Young et al., 2009). 
 A total of 50 samples provided data on participants of predominantly 
European ancestry, and seven on participants of other ancestry. Twenty-one samples 
reported data on control/population samples, and 36 on disease/partial disease 
samples (e.g., lung cancer cases). Forty-four samples reported data on rs1051730, 
and 27 on rs16969968 (NB: k = 15 samples reported data on both SNPs). Two 
samples reported genotype frequencies that deviated substantially from HWE (NB: 
one additional non-HWE sample was excluded from analyses as the homozygous 
risk genotype group contained only one participant). Minor allele frequencies of 
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rs16969968 (A) and rs1051730 (T) ranged from 0.03-0.43 (median = 0.35). The wide 
ranges were primarily driven by the inclusion of non-European samples in which the 
minor alleles were rare.  
2.3.3 Smoking quantity 
 Primary analyses. Meta-analysis indicated strong evidence of association 
between the rs1051730/rs16966968 variants and daily cigarette consumption (Fixed-
effects: B = 0.91, 95% CI 0.77, 1.06, p <0.001; Random effects: B = 1.01, 95% CI 
0.81, 1.22, p <0.001) (Table 2.3, Figure 2.2).  There was evidence of moderate 
between-study heterogeneity (Q [56] = 85.46, p = 0.007, I² = 34%). Regression 
coefficient units refer to increases/decreases in daily cigarette consumption per copy 
of the minor allele(s). 
 Egger’s test indicated weak evidence of small study bias (t [55] = 1.84, pone-
tailed  = 0.036). This is visually presented in a funnel plot in Figure 2.3. To adjust for 
this we utilised Duval and Tweedie’s ‘trim and fill’ method (Duval & Tweedie, 
2000). This method removes studies with outlying effect size values identified on 
funnel plots until symmetry is achieved, and then replaces these along with imputed 
“mirror” values in order to retain symmetry. This correction had minimal effect on 
the overall effect estimate (adjusted value: B = 0.85, 95% CI 0.62, 1.07). There was 
no evidence of an association between effect size estimate and year of publication (B 
= -0.17, 95% CI -0.47, 0.13, p = 0.27). 
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Table 2.3. Meta-analysis of rs1051730/rs16966968 and heaviness of smoking: Full and stratified analyses. 
 
  Fixed effects Random effects 
 k Effect size 95% CI p-value I
2
 pdiff Effect size 95% CI p-value pdiff 
Full model 57 0.915 0.769 1.060 <0.001 34% NA 1.012 0.806 1.218 <0.001 NA 
HWE             
  Yes 55 0.898 0.752 1.045 <0.001 34% 
0.089 
0.989 0.781 1.196 <0.001 
0.12 
  No 2 1.894 0.757 3.032 0.001 0% 1.894 0.757 3.032 0.001 
Ancestry             
  European 50 0.887 0.739 1.036 <0.001 34% 
0.059 
0.971 0.763 1.178 <0.001 
0.18 
  Other 7 1.634 0.874 2.394 <0.001 20% 1.584 0.712 2.456 <0.001 
Disease state             
 No 21 0.838 0.533 1.143 <0.001 33% 
0.57 
0.968 0.547 1.390 <0.001 
0.79 
Yes/Partial 36 0.937 0.772 1.103 <0.001 37% 1.035 0.798 1.273 <0.001 
SNP             
rs1051730 44 1.144 0.964 1.323 <0.001 19% 
<0.001 
1.170 0.952 1.388 <0.001 
0.028 
rs16969968 27 0.648 0.444 0.852 <0.001 30% 0.775 0.499 1.051 <0.001 
 
Results under an additive model of genetic action displayed.  
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Figure 2.2. Meta-analysis of association of rs1051730/rs16969968 with heaviness of 
smoking. 
 
Results under an additive model of genetic action displayed. Data analysed within a 
random-effects framework. Results from individual studies are listed in order 
according to year of publication. 
Individual estimates weighted using Der Simonian and Laird methods. Overall effect 
size: B = 1.01, 95% CI 0.81, 1.22, p<0.001. Point estimates refer to 
increases/decreases in daily cigarette consumption, units representing whole 
cigarettes. 
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Figure 2.3. Funnel plot illustrating evidence of small study bias in pooled meta-
analysis. 
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 Stratified analyses. Results from all stratified analyses, under both fixed- and 
random-effects models, are displayed in Table 2.3. Random-effects model outcomes 
are presented here. Evidence for an association between rs1051730/rs16969968 
variants and heaviness of smoking was observed irrespective of stratification by 
study level characteristics. 
Two of the 57 samples included in our analysis deviated from HWE. We 
compared this pair of samples to the group of 55 samples which did not deviate from 
HWE. In both groups there was strong evidence to suggest an association between 
rs1051730/rs16969968 and daily cigarette consumption (HWE: B = 0.99, 95% CI 
0.78, 1.20, p <0.001; Non-HWE: B = 1.89, 95% CI 0.76, 3.03, p = 0.001).There was 
no clear evidence to suggest a difference in effect size estimates between groups (pdiff 
= 0.12). 
There was strong evidence of an association between rs1051730/rs16969968 
and daily cigarette consumption in both European and Other groups (European: B = 
0.97, 95% CI 0.76, 1.18, p <0.001; Other: B = 1.58, 95% CI 0.71, 2.46, p 
<0.001).There was no clear evidence to suggest that this effect size differed between 
groups (pdiff = 0.18). 
There was strong evidence of an association between rs1051730/rs16969968 
and daily cigarette consumption in both the control/population group and the 
disease/partial disease group (control: B = 0.97, 95% CI 0.55, 1.39, p <0.001; 
disease/partial: B = 1.04, 95% CI 0.80, 1.27, p <0.001). There was no evidence for a 
difference in effect size estimates between groups (pdiff = 0.79).  
There was strong evidence of an association between both rs1051730 and 
rs16969968 SNPs and daily cigarette consumption (rs1051730: B = 1.17, 95% CI 
0.95, 1.39, p <0.001; rs16969968: B = 0.77, 95% CI 0.50, 1.05, p <0.001), and this 
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effect size appeared to differ between groups (p = 0.028). However, although this 
difference was qualitatively observed in the sub-set of samples (k = 14) which 
contained data on both SNPs, with a slightly larger effect size observed for 
rs1051730 (B = 1.09, 95% CI 0.72, 1.46, p <0.001) compared with rs16966968 (B = 
1.05, 95% CI 0.65, 1.46, p <0.001), this difference did not achieve statistical 
significance (pdiff = 0.89), suggesting that the observed difference in the full meta-
analysis may be due to confounding arising from other study- or sample-level 
differences. One sample reporting data on both SNPs was excluded from analyses as 
the homozygous risk genotype group contained only one participant. 
Egger’s test indicated no evidence of small study bias for SNP rs1051730 (t 
[42] = 0.92, pone-tailed = 0.18). Evidence of small study bias was observed for SNP 
rs16969968 however (t [25] = 2.01, pone-tailed = 0.028). We utilised Duval and 
Tweedie’s ‘trim and fill’ method to adjust for this, which led to a reduction in the 
overall effect estimate for this SNP (adjusted value: B = 0.49, 95% CI 0.19, 0.79). 
2.4 Discussion 
Our data suggest compelling evidence for a small effect of the 
rs16969968/rs1051730 SNPs on daily cigarette consumption, equivalent to a per 
allele effect of approximately one cigarette per day. Interestingly, rs1051730 may 
provide a stronger signal than rs16969968, although evidence for this is indirect and 
should therefore be treated with caution. No evidence for a difference in effect size 
between groups was observed in other stratified analyses (i.e., ancestry, disease 
state). Strong evidence for an association between rs16969968/rs1051730 SNPs and 
daily cigarette consumption was observed irrespective of study level characteristics, 
suggesting that the association is robust. 
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The nicotinic acetylcholine receptor, to which nicotine binds, is a plausible 
and biologically relevant candidate for smoking aetiology, as previously discussed 
(Chapter 1). Although the mis-sense mutation rs16969968 appears to be of functional 
significance, a larger effect was observed for the synonymous SNP rs1051730 in full 
stratified analyses. Whilst this variant appears to be of no functional significance, 
which to some extent limits the interpretation of the observed association, as a single 
marker it appears superior to rs16969968 with regards to determining variation in 
smoking quantity. It is also noteworthy that evidence of small study bias was 
observed for rs16969968 but not for rs1051730. Adjusting for this bias increased the 
difference in effect estimate between variants. It is possible that rs1051730 is a 
strong tagging SNP for functional haplotypes in this region and it would therefore be 
important to focus research efforts on identifying these. It is crucial to note however 
that the difference in effect size estimates between variants was only qualitatively 
observed in the subset of samples which contained data on both rs1051730 and 
rs16969968. This may be due to the limited number of studies examined (k = 14) or 
driven by other study- or sample-level differences. A large scale study directly 
comparing both variants would be required to answer this question definitively. 
The primary limitation of our meta-analysis was that we did not have the data 
necessary to perform a joint SNP analysis in which the effects of one variant were 
conditioned on the other. This analysis would have enabled us to comment more 
authoritatively on the difference in genetic signal between these two SNPs, if any, 
which are known to be in linkage disequilibrium (LD). Linkage disequilibrium refers 
to the non-random association of alleles at different loci, and may be inferred from 
genotype frequency data. The strength of association between loci may be assessed 
using different measures, including r
2
 and D’. These measures range from 0 (no 
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disequilibrium) to 1 (complete disequilibrium) (Wall & Pritchard, 2003). The strong 
LD observed between the variants examined here (European: r
2
 = 0.902, 
Japanese/Chinese: r
2
 = 1.000, African: r
2
 = unavailable; calculated using HapMap 
data in conjunction with SNAP 
[http://www.broadinstitute.org/mpg/snap/ldsearchpw.php]) is certainly likely to have 
impacted on our ability to detect differences in effect estimates between SNPs. A 
large-scale study would certainly be required to detect potential differences. An 
additional limitation of our meta-analysis was that the procedures used allowed only 
comparable data to be combined. As such a number of studies that would have 
ideally been included in our analysis had to be excluded, such as those examining 
extreme smoking quantity phenotypes (e.g., Stevens et al., 2008). We were also 
unable to include data from studies reporting only categorical smoking quantity data 
by genotype (e.g., Thorgeirsson et al., 2008). An additional shortcoming was that we 
were only able to investigate a limited number of study-level characteristics. It is of 
note, however, that the analysis of study-level characteristics is indirect, and may 
lead to ecological fallacy. Any differences observed should be considered 
hypothesis-generating to be followed-up in appropriately designed primary studies. 
Additionally, it is of note that methods employed to correct for publication bias, such 
as Duval & Tweedie’s ‘trim and fill’ approach as utilised here, are not widely 
accepted and rest on certain assumptions (see Munafo, Clark, & Flint, 2004). As 
such, corrected findings should be interpreted with caution. Finally, a comprehensive 
assessment of study quality and potential bias was not considered in this meta-
analysis. As Little et al. (2009) highlight, the manner in which a study is conducted 
and choices made regarding study design and data analysis may all potentially 
influence the magnitude and direction of results in genetic association studies. 
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Potential methods for incorporating information on study quality into meta-analyses 
include quality weighting (Rosenthal, 1991) and subgroup analysis by quality. Whilst 
we did not assess and consider all aspects of study quality and potential sources of 
bias, we did conduct subgroup analyses contrasting samples which did and did not 
deviate from HWE. Deviations from HWE are typically indicative of genotyping 
error which can impact study power. No difference in effect size was observed 
between these two groups however. 
In conclusion, our analyses confirm that two variants (rs16969968 and 
rs1051730) located in the nicotinic acetylcholine receptor gene cluster CHRNA5-A3-
B4 are robustly associated with heaviness of smoking. Interestingly, rs1051730 may 
provide a stronger signal than rs16969968, although evidence for this is indirect. 
Much variability in this phenotype remains to be determined however. Smoking is a 
complex behaviour determined by both genetic and environmental factors. It is likely 
that many other loci will contribute to this phenotype, as will multiple environmental 
factors. It is also important to also consider gene-gene interactions (epistasis), as well 
as gene-environment interactions, whereby the expression of a genetic effect is 
modified by environmental exposure(s). It is of note that genetic influences on 
smoking phenotypes such as heaviness of smoking and nicotine dependence can only 
be expressed following initial exposure to tobacco. Therefore, environmental factors 
which influence likelihood of initial exposure are of particular interest, as they hold 
the potential to modify expression of genetic effects. This is explored further in the 
following chapter.
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Chapter 3 
Genetic Epidemiology:  
The Association between CHRNA3, BDNF, Parental Monitoring and Smoking 
Initiation: A Longitudinal Study 
3.1 Introduction 
3.1.1 The Avon Longitudinal Study of Parents and Children 
 The Avon Longitudinal Study of Parents and Children (ALSPAC) 
(http://www.alspac.bris.ac.uk) has been an essential resource for the completion of 
my doctoral studies. Both the current and subsequent experimental chapters of this 
thesis are based on data gathered from (or plans to gather from) ALSPAC 
participants. Within this section we discuss ALSPAC in detail, and highlight why it 
is particularly well-suited for the study of behavioural genetics.  
 The Avon Longitudinal Study of Parents and Children, also known as 
‘Children of the 90s’, is a transgenerational prospective observational study (Boyd et 
al., 2012). It was founded to establish how genetic and environmental factors 
influence health and development (Fraser et al., 2012). In brief, 14,541 pregnant 
women resident in the former county of Avon, UK, with expected delivery dates 
between 1
st
 April 1991 and 31
st
 December 1992 were recruited for this study. At the 
planning stages of ALSPAC, the Avon population was considered similar to that of 
the whole of Great Britain (Golding, Pembrey, & Jones, 2001). Phenotypic and 
environmental data, alongside genetic information and biological samples, have been 
collected from mothers and their offspring at multiple time points throughout the 
course of the study (Boyd et al., 2012). The breadth and frequency of data collection, 
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including the availability of repeat measures, is a particular strength of the study, and 
of particular importance to the reported scheme of work.  
“The ALSPAC resource has a scale and richness that is unprecedented in 
epidemiological studies” 
(Boyd et al., 2012, p9) 
Data on the children have been collected at 68 time points between birth and 
18 years of age. This has included 34 child-completed questionnaires, nine clinical 
assessments (“Focus” clinics), and 25 questionnaires about the child completed by 
mothers/primary caregivers (Boyd et al., 2012). Data on smoking behaviour (as 
reported by the child) has been collected in brief at the ages of eight and 10 years 
(clinic setting), and in more detail at the ages of 12, 13, 14, 15, 16 and 17 years 
(assessed in a clinic setting or reported via postal questionnaire).  
Data on the mothers has been ascertained through 18 self-report 
questionnaires (from pregnancy to 20 years postnatal), medical records, opportunistic 
clinic assessments, and a recent clinic assessment focused specifically on mothers 
(FoM1) (Fraser et al., 2012). A wealth of data has been collected on maternal 
smoking behaviour at multiple time points throughout the study. This includes 
information on smoking during pregnancy. 
 DNA samples are available for 11,343 children and 10,321 mothers. 
Genome-wide data are available for 8,365 children and over 10,000 mothers, and 
complete genome sequencing data will soon be available for 2,000 children. DNA 
methylation data for 1,000 mother and child pairs are also pending (Boyd et al., 
2012; Fraser et al., 2012). 
 The large sample size, richness of phenotypic and environmental data, 
combined with the availability of genetic information, make ALSPAC a particularly 
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well-suited resource for the study of behavioural genetics, including the field of 
molecular genetics. 
3.1.2 CHRNA3, BDNF, parental monitoring and smoking initiation 
An estimated 82,000 to 99,000 young people worldwide start smoking every 
day (Lando et al., 2010). In order to develop appropriate preventative measures, it is 
important to identify the causes of smoking initiation, and also factors underlying 
progression from first use to dependence. 
In a recent meta-analysis of genome-wide association studies of smoking 
behaviours, a nonsynonymous single nucleotide polymorphism (SNP) rs6265 in 
BDNF, which encodes brain-derived neurotrophic factor, was found to be most 
strongly associated with smoking initiation, determined through comparison of ever 
versus never smokers (Furberg et al., 2010). BDNF plays an important role in the 
survival and differentiation of dopaminergic neurons, and has previously been linked 
to substance use (Gratacos et al., 2007). Another genetic variant that has proven of 
particular importance in relation to smoking-related phenotypes is rs1051730 in 
CHRNA3 (as discussed previously). Although an association between this locus and 
smoking initiation has not been observed, it has previously been associated with 
positive initial smoking experiences (Sherva et al., 2008), and has been consistently 
associated with other smoking-related phenotypes. 
Genetic influences on smoking phenotypes such as nicotine dependence can 
only be expressed following initial exposure to tobacco. Therefore, environmental 
factors which influence likelihood of initial exposure may modify the expression of 
genetic effects. One such factor of a priori relevance is parental monitoring. A 
substantial body of evidence has demonstrated an association between level of 
parental monitoring and adolescent substance use, including smoking (Bohnert, Rios-
Chapter 3  Genetic Epidemiology 
68 
 
Bedoya, & Breslau, 2009; Chilcoat, Dishion, & Anthony, 1995; Piko & Kovacs, 
2010; Pokhrel, Unger, Wagner, Ritt-Olson, & Sussman, 2008). The relationship 
consistently demonstrated between level of monitoring and smoking initiation may 
be explained as follows: Adolescents who are poorly monitored by parents/guardians 
are more likely to be regularly exposed to ‘risky’ environments where cigarettes are 
available, and/or to smoking peers, thus increasing risk of smoking initiation, whilst 
the converse is true for closely monitored children. 
In addition to its well-established, independent effect on smoking behaviour, 
parental monitoring has also been reported to modify genetic risk for smoking. In a 
study of Finnish twins, Dick et al. (2007) showed that the relative importance of 
genetic influences on smoking behaviour changed substantially as a function of 
parental monitoring, genetic effects significantly decreasing in importance as 
parental monitoring levels increased. The primary interpretation drawn from this 
study was that a background of low parental monitoring created an environment 
allowing for greater opportunity to express genetic predispositions. Building upon 
these findings, researchers have now begun to explore the impact of environmental 
factors on associations between specific genes and smoking-related phenotypes. 
Chen et al. (2009), for example, recently examined whether level of parental 
monitoring during early adolescence modified the risk of nicotine dependence 
associated with rs16969968 in a US-based community sample. Both parental 
monitoring and rs16969968 were associated with risk of nicotine dependence. In 
addition, and of key interest here, expression of the genetic effect was modified by 
parental monitoring level; risk for nicotine dependence significantly increased with 
the risk genotype of rs16969968 when combined with the lowest quartile of parental 
monitoring. It is of note that the study of gene × environment interactions, 
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exemplified by Caspi et al. (2003), has come under substantial criticism in recent 
years (e.g., Flint & Munafo, 2008; Munafo & Flint, 2009). This approach was borne 
from the notion that such interactions may “illuminate the aetiology and genetic 
architecture of behavioural phenotypes” (Munafo & Flint, 2009). However, 
inconsistencies and persistent failures to replicate effects have dominated this field of 
research. One likely reason for this is the potential this approach offers for data 
dredging (i.e., manipulation of multiple parameters), and associated use of multiple 
(and often unreported) statistical tests.  Such techniques may be utilised to identify 
‘significant’, and thus publishable, findings, yet serve only to confuse the existent 
literature. It is important to note at this juncture that in this study we have a strong a 
priori reason for expecting the effect of interest to be restricted to a specific 
subgroup. Our primary variant of interest, rs1051730, is located in a gene responsible 
for encoding the α3 nicotinic receptor subunit, thus expression of its effect may only 
be expressed following initial exposure to tobacco. As discussed, adolescents who 
are poorly monitored are likely to experience opportunities to smoke, and smoke 
regularly, thus enabling expression of said genetic effect. 
Smoking initiation, considered as a binary outcome, has limitations with 
respect to understanding the complex processes involved in smoking acquisition. 
Whilst many adolescents will try a cigarette (i.e., very first use), not all will progress 
through experimentation to regular use. Heritability estimates differ for initiation 
relative to progression of smoking (Fowler et al., 2007), suggestive of differing 
underlying causes. These issues have been discussed at length elsewhere (National 
Cancer Institute, 2009). It is therefore important to consider initial smoking 
trajectories. By capturing the complexities of initial cigarette use, these may prove to 
be more informative phenotypes for examination in genetic association studies. 
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Using data from a prospectively assessed cohort, we sought to determine the 
association between rs6265 (BDNF) and rs1051730 (CHRNA3) and smoking 
initiation. The variant rs6265 was included to serve as a positive control given its 
previously established association with initiation. Initiation was assessed both in 
terms of ‘ever use’ of cigarettes, and also in terms of initial smoking trajectories – a 
novel, sophisticated phenotype which captures the complexities of initial cigarette 
use, determined using repeated measures of smoking frequency. Given that 
rs1051730 is located in a gene responsible for encoding the α3 nicotinic receptor 
subunit, it was hypothesised that its effects would not be associated with ever (i.e., 
very first) use of cigarettes, but may be associated with initial smoking trajectories, 
namely those capturing progression from initial exposure to tobacco (engaging 
nicotinic receptors) through to regular use. We also sought to determine potential 
modification in the expression of these genetic effects by a well-established 
environmental risk factor for smoking initiation, namely parental monitoring. Given 
that this variable may plausibly influence the probability of exposure to 
tobacco/opportunities to smoke, I hypothesised that level of parental monitoring 
would moderate the expression of the predicted genetic effect. 
3.2 Methods 
3.2.1 Participants 
All participants were drawn from ALSPAC (Boyd et al., 2012). From an 
initial 14,541 pregnancies, with a total of 14,676 foetuses, 14,062 live births took 
place.  For reasons of confidentiality, data on the 13 triplet and quadruplet children 
were not available for analysis. Our starting sample consisted of the 13,976 
singletons and twins who survived until one year of age. Ethics approval for this 
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study was obtained from the ALSPAC Ethics and Law Committee, which is 
registered as an Institutional Review Board. 
3.2.2 Measurements 
Smoking initiation. Smoking ‘initiation’ was assessed using two distinct 
measures: 1. Ever use of cigarettes; and 2. Initial trajectories of smoking behaviour. 
Ever use data was collected at age 16 years via a postal questionnaire. This was the 
most recent wave of data available at time of analysis. The specific question posed 
was as follows: “Have you ever smoked a cigarette (including roll-ups)?”, to which 
participants responded “yes” or “no”. Derivation of initial smoking trajectory 
categories is described in full in Heron et al. (2011). This approach was adopted to 
examine smoking trajectory phenotypes in the current study. Briefly, latent class 
analysis was used to analyse repeated measures of smoking frequency in the 
ALSPAC cohort (data gathered at ages 14, 15 and 16 years), enabling the 
identification of distinct smoking behaviour profiles. Smoking frequency was 
defined as a four-category ordinal variable comprised of the following categories: 
“none”; “less than weekly”; “weekly”; “daily”. Four distinct initial trajectories of 
smoking behaviour were determined: non-smokers, experimenters, late-onset regular 
smokers, and early-onset regular smokers. Each individual in our sample was 
assigned a probability of belonging to each of these four categories based on repeated 
measures of smoking behaviour collected at ages 14, 15, and 16 years. The data 
gathered at ages 14 and 16 years were collected via postal questionnaire, whilst the 
data gathered at age 15 years were collected in a clinic setting via a computer 
terminal. Multiple imputation was used to enable classification of individuals with 
partially missing data to a particular trajectory, thus enabling us to maximise sample 
size (see Figure 3.2). 
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Genetic data. DNA was extracted as described previously (Jones et al., 2000). 
Genotyping was undertaken by KBioscience Ltd. (www.kbioscience.co.uk), using a 
proprietary competitive allele specific PCR system (KASPar) for SNP analysis. For 
this study we focused on two SNPs, namely rs6265 (BDNF) and rs1051730 
(CHRNA3). 
 Parental monitoring. Level of parental monitoring was assessed in a clinic 
setting. It was assessed at age 11 years, thus preceding our assessment of smoking 
behaviour in the children. Parents/guardians were not present. During a short, 
structured interview the children were asked three questions pertaining to parental 
monitoring: 1. Whether the grown-ups that they live with knew all the other children 
that the child ‘hangs around’ with (responses: yes, all; quite a lot; a few; none); 2. 
Whether grown-ups knew about what the child did with other children (responses: 
everything; most things; few things; nothing); and 3. Whether the child would ask a 
grown up for help if they were having problems with their friends or other children 
(responses: yes; most of the time; occasionally; definitely not). Responses were made 
on a four-point scale, scored zero to three. The participant’s responses to these three 
items were summed to form a total score ranging between zero and nine, higher 
scores indicating lower levels of parental monitoring. Given the uneven distribution 
of scores (approximately 85% of individuals scored between zero and three in both 
samples), application of pre-specified cut-points based on score were prohibited due 
to low cell counts. As such, post-hoc determination of cut-points was required. 
Scores of zero, one, two and three were grouped into category ‘0’ (~85% of 
samples), and scores ranging from four to nine into category ‘1’ (~15% of samples).. 
Given this somewhat unorthodox approach to category classification, sensitivity 
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analyses examining the effect of altering this cut-off were also conducted (see 
Section 3.3.5). 
3.2.3 Statistical analyses 
 A series of chi-square tests were first conducted to explore associations 
between genetic variants, parental monitoring, and each of the smoking initiation 
phenotypes. Several additional variables previously identified as risk factors for 
initial smoking trajectories were also analysed, including: sex, housing tenure (coded 
as owned/mortgaged, privately rented, subsidised housing), crowding status (coded 
as the ratio of number of residents to number of rooms in house), maternal education 
attainment (coded as no high school qualifications, high school, beyond high school), 
maternal smoking during pregnancy (first trimester), and parity (coded as whether 
study child was first, second, third child or greater) (see Heron et al., 2011). 
 Logistic regression was used to test main effects of both variants and parental 
monitoring on smoking initiation (ever use), and to investigate gene-environment 
interactions. Multinomial logistic regression was used for initial smoking trajectory 
analyses. Additional regression analyses were conducted including the covariates 
outlined above, which had been selected for inclusion in regression models a priori 
given their previous identification as risk factors for smoking initiation. In all 
instances, likelihood ratio tests were utilised to compare log likelihood values 
between statistical models. Genetic variants were considered as linear variables for 
the purposes of analysis, coded in terms of frequency of the minor allele (i.e., 0, 1 or 
2). A χ2 test was used to assess whether or not the genotype frequencies of both SNPs 
were in Hardy-Weinberg equilibrium. 
 All statistical analyses were conducted using Stata version 11.1. 
 
Chapter 3  Genetic Epidemiology 
74 
 
3.3 Results 
3.3.1 Sample derivation 
 The initial sample for both sets of analyses consisted of the 13,976 singletons 
and twins in the ALSPAC cohort who survived until one year of age. However, our 
final samples were considerable smaller (see Figures 3.1 and 3.2), due to sample 
attrition. We further restricted analyses to individuals with the required data on 
smoking behaviour (at ages 14, 15 and/or 16 years), parental monitoring (at age 11 
years) and genetics. Individuals who had reported ever smoking at 10 years (i.e., 
prior to the parental monitoring assessment) were excluded, and our final sample was 
limited to individuals of European ancestry. Our final samples thus consisted of 
2,687 and 3,771 individuals for ever use and smoking trajectory analyses 
respectively. Figures 3.1 and 3.2 illustrate participant flow. 
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Figure 3.1. Ever use sample – participant flow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Starting sample:  
Singletons/twins who survived at 
least until 1 year of age 
n=13,976 
Invited to complete 
questionnaire at age 16 years 
n=9,510 
Completed questionnaire at age 
16 years 
n=4,901 
Provided smoking initiation 
information  
n=4,868 
Did not answer “yes” to ever 
smoking at age 10y 
n=4,841 
Genotype data available  
(rs6265 and rs1051730) 
n=3,509 
Parental monitoring data 
available at age 11y (all 3 items) 
n=2,956 
Gender/age/other confounder* 
data available 
n=2,784 
Final sample for analysis 
n=2,687 
*Confounders: 
 
 Housing tenure 
 Overcrowding 
 Maternal smoking 
during pregnancy 
 Parity 
 Maternal education 
 
Individuals of European ancestry 
n=2,687 
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Figure 3.2. Smoking trajectories sample – participant flow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Starting sample:  
Singletons/twins who survived at 
least until 1 year of age 
n=13,976 
Data available on smoking 
frequency collected at one or 
more of the following time 
points: 14y; 15y6m; 16y6m 
 
one response n=2,052 
two responses n=2,232 
three responses n=3,038 
 
n=7,322 
 
Did not answer “yes” to ever 
smoking at age 10y 
n=7,268 
Genotype data available  
(rs6265 and rs1051730) 
n=5,158 
Parental monitoring data 
available at age 11y (all 3 items) 
n=4,226 
Gender/age/other confounder* 
data available 
n=3,913 
Final sample for analysis 
n=3,771 
*Confounders: 
 Housing tenure 
 Overcrowding 
 Maternal smoking 
during pregnancy 
 Parity 
 Maternal education 
Individuals of European ancestry 
n= 3,771 
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3.3.2 Characteristics of participants 
Ever use sample. Approximately one half of the sample reported having ever 
smoked a cigarette by the age of 16 (see Table 3.1 for sample characteristics), with 
girls being more likely than boys to have tried smoking by this age (p < 0.001). Other 
factors influencing ever use of cigarettes by this age included overcrowding in the 
home (p = 0.006), maternal smoking during pregnancy (p < 0.001), and parity (p < 
0.001). Genotype frequencies for rs1051730 were: C:C 45.4% C:T 43.0% T:T 
11.6%, and for rs6265 were: G:G 66.8% G:A 29.4% A:A 3.8%. These genotype 
frequencies were in Hardy-Weinberg equilibrium (rs1051730: p = 0.13; rs6265: p = 
0.17). 
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Table 3.1. Sample characteristics for ever use of cigarettes.  
 Total 
Ever smoked 
by 16y 
Never smoked 
by 16y 
χ² test 
p 
value 
 n % n % n %  
Total 2687 100% 1278 47.6% 1409 52.4%  
Gender        
    Male  1137 42.3% 426 33.3% 711 50.5% 
<0.001 
    Female 1550 57.7% 852 66.7% 698 49.5% 
SNP rs1051730        
    CC  1221 45.4% 599 46.9% 622 44.1% 
0.35     CT 1155 43.0% 537 42.0% 618 43.9% 
    TT 311 11.6% 142 11.1% 169 12.0% 
SNP rs6265        
    GG 1794 66.8% 840 65.7% 954 67.7% 
0.16     GA 790 29.4% 395 30.9% 395 28.0% 
    AA 103 3.8% 43 3.4% 60 4.3% 
Parental monitoring level        
    0 (highest) 2298 85.5% 1058 82.8% 1240 88.0% 
<0.001 
    1 (lowest) 389 14.5% 220 17.2% 169 12.0% 
Housing tenure        
    Mortgaged/owned 2389 88.9% 1128 88.3% 1261 89.5% 
0.53     Rented 169 6.3% 83 6.5% 86 6.1% 
    Subsidised 129 4.8% 67 5.2% 62 4.4% 
Overcrowding        
    ≤0.5 person/room 1465 54.5% 665 52.0% 800 56.8% 
0.006 
    >0.5 – 0.75 person/room 811 30.2% 389 30.4% 422 30.0% 
    >0.75 – 1 person/room 347 12.9% 194 15.2% 153 10.9% 
    >1 person/room 64 2.4% 30 2.3% 34 2.4% 
Smoking during pregnancy        
    No 2322 86.4% 1065 83.3% 1257 89.2% 
<0.001 
    Yes 365 13.6% 213 16.7% 152 10.8% 
Parity        
    First child 1299 48.3% 575 45.0% 724 51.4% 
<0.001     Second child 964 35.9% 470 36.8% 494 35.1% 
    Third child or higher 424 15.8% 233 18.2% 191 13.6% 
Maternal education        
    Qualifications > high school 1363 50.7% 631 49.4% 732 52.0% 
0.23     High school qualifications 905 33.7% 433 33.9% 472 33.5% 
    No high school qualifications 419 15.6% 214 16.7% 205 14.5% 
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Smoking trajectories sample. Of this sample, 81.7% were classified as non-
smokers, whilst 8.8% were classified as experimenters, 6.6% as late-onset regular 
smokers, and 2.8% as early-onset regular smokers (see Table 3.2 for sample 
characteristics). Exact sample sizes within each trajectory cannot be specified as 
these values are based on probabilities. Other factors influencing initial smoking 
trajectories included sex (p < 0.001), housing tenure (p < 0.001), overcrowding (p < 
0.001), maternal smoking during pregnancy (p < 0.001), parity (p < 0.001), and level 
of maternal education (p < 0.001), as previously reported by Heron et al. (2011). 
Genotype frequencies for rs1051730 were: C:C 45.2% C:T 43.7% T:T 11.1%, and 
for rs6265 were: G:G 66.9% G:A 29.0% A:A 4.1%. Genotype frequencies for 
rs1051730 were in Hardy-Weinberg equilibrium (p = 0.51), although they were not 
for rs6265 (p = 0.008).
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Table 3.2. Sample characteristics for initial smoking trajectories. 
 
 
Total 
Non-
Smoker 
Experi-
menter 
Late-
Onset 
Regular 
Early-
Onset 
Regular 
χ² test p 
value 
 n % % % % %  
Total 3771 100% 81.7% 8.8% 6.6% 2.8%  
Gender        
    Male 1779 47.2% 85.1% 7.3% 5.3% 2.3% 
<0.001 
    Female 1992 52.8% 78.7% 10.2% 7.8% 3.3% 
SNP rs1051730        
    CC 1703 45.2% 80.9% 8.7% 7.3% 3.1% 
0.19     CT 1649 43.7% 82.0% 9.2% 6.2% 2.7% 
    TT 419 11.1% 84.3% 8.2% 5.7% 1.8% 
SNP rs6265        
    GG 2524 66.9% 81.5% 8.9% 6.8% 2.8% 
0.89     GA 1092 29.0% 82.1% 8.9% 6.3% 2.7% 
    AA 155 4.1% 83.2% 7.8% 5.9% 3.1% 
Parental monitoring level        
    0 (highest) 3143 83.4% 83.3% 8.5% 5.9% 2.3% 
<0.001 
    1 (lowest) 628 16.7% 73.9% 10.6% 10.3% 5.2% 
Housing tenure        
    Mortgaged/owned 3286 87.1% 82.2% 8.9% 6.5% 2.4% 
<0.001     Rented 246 6.5% 80.6% 8.9% 7.0% 3.6% 
    Subsidised 239 6.3% 75.9% 8.1% 8.4% 7.7% 
Overcrowding        
    ≤0.5 person/room 1990 52.8% 83.8% 8.8% 5.7% 1.8% 
<0.001 
    >0.5 – 0.75 person/room 1165 30.9% 81.3% 8.1% 7.0% 3.6% 
    >0.75 – 1 person/room 507 13.4% 76.5% 10.6% 9.0% 3.9% 
    >1 person/room 109 2.9% 73.5% 10.8% 8.2% 7.5% 
Smoking during pregnancy        
    No 3209 85.1% 83.3% 8.7% 6.1% 2.0% 
<0.001 
    Yes 562 14.9% 72.7% 9.9% 9.8% 7.6% 
Parity        
    First child 1779 47.2% 84.4% 8.1% 5.5% 2.1% 
<0.001     Second child 1371 36.4% 80.2% 9.4% 7.5% 3.0% 
    Third child or higher 621 16.5% 77.5% 9.8% 8.3% 4.4% 
Maternal education        
    Qualifications > high school 1757 46.6% 83.0% 9.4% 5.7% 1.9% 
<0.001     High school qualifications 1336 35.4% 81.0% 8.6% 7.3% 3.2% 
    No high school qualifications 678 18.0% 79.7% 7.8% 8.0% 4.5% 
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3.3.3 Associations of genotype and parental monitoring with smoking behaviour 
Logistic regression models of smoking initiation are shown in Tables 3.3 and 
3.4. We found strong evidence of an association between parental monitoring and 
smoking initiation, both for ever use (unadjusted: p < 0.001) and smoking trajectories 
(unadjusted:  p < 0.001). This association remained after adjusting for covariates (ps 
< 0.001).  Individuals who were poorly monitored were more likely to report ever 
use of cigarettes by the age of 16 relative to those who were well monitored. These 
individuals were also more likely to be classed as experimenters and regular smokers 
(both late-onset and early-onset). Of note, the effect of poor parental monitoring on 
smoking increased in a relatively linear fashion across the smoking trajectory 
categories, and was most pronounced in the early-onset regular smoking category 
(which may be considered the most ‘severe’ category).  
 Contrary to expectations, we found no evidence for an association between 
rs6265 and either smoking initiation phenotype in unadjusted or adjusted analyses 
(ps > 0.52). No evidence of an association was noted between rs1051730 and ever 
use of cigarettes (ps > 0.16). Curiously, however, there was some weak  evidence of 
an association between this variant and initial smoking trajectories in adjusted 
analyses (ps > 0.09) , although in the opposite direction to that predicted, with the T 
allele (associated previously with increased daily cigarette consumption and nicotine 
dependence) marginally protective for late-onset and early-onset regular smoking. 
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Table 3.3. Logistic regression models of ever use of cigarettes. 
 Unadjusted Adjusted* 
  95% CI   95% CI  
 OR LB UB p OR LB UB p 
Parental monitoring 1.53 1.23 1.89 <0.001 1.71 1.36 2.13 <0.001 
SNP rs6265 ( A) 1.04 0.90 1.19 0.61 1.05 0.91 1.20 0.53 
SNP rs1051730 (T) 0.92 0.83 1.03 0.17 0.92 0.82 1.03 0.16 
Highest level of parental monitoring used as reference category for parental 
monitoring. SNPs were coded in terms of number of copies of the minor allele 
(identified in brackets), ‘0’ being the reference category in both instances. *Results 
adjusted for sex, housing tenure, overcrowding, smoking during pregnancy, parity, 
maternal education. 
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Table 3.4. Logistic regression models of initial smoking trajectories.  
 Unadjusted Adjusted* 
 Experimenters Late-Onset Regular Early-Onset Regular p Experimenters Late-Onset Regular Early-Onset Regular p 
 
OR 
95% CI 
OR 
95% CI 
OR 
95% CI  
OR 
95% CI 
OR 
95% CI 
OR 
95% CI  
 LB UB LB UB LB UB  LB UB LB UB LB UB  
Parental Monitoring 1.41 1.06 1.87 1.96 1.46 2.65 2.55 1.67 3.89 <0.001 1.50 1.12 2.01 2.14 1.58 2.92 2.86 1.84 4.46 <0.001 
SNP rs6265 (A) 0.97 0.79 1.19 0.91 0.72 1.16 0.99 0.70 1.40 0.89 0.97 0.79 1.19 0.91 0.72 1.15 0.99 0.70 1.40 0.88 
SNP rs1051730 (T) 0.98 0.83 1.17 0.84 0.70 1.03 0.79 0.59 1.07 0.19 0.99 0.83 1.17 0.83 0.68 1.02 0.75 0.55 1.02 0.09 
 
 
Non-smokers used as reference category for smoking trajectory categories. Highest level of parental monitoring used as reference category for 
parental monitoring. SNPs were coded in terms of number of copies of the minor allele (identified in brackets), ‘0’ being the reference category 
in both instances. *Results adjusted for sex, housing tenure, overcrowding, smoking during pregnancy, parity, maternal education.
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3.3.4 Moderation by parental monitoring 
 There was no evidence of an interaction between parental monitoring and 
rs6265 or rs1051730 for either initiation phenotype (ps > 0.35). 
3.3.5 Sensitivity analyses 
 Altering the cut-off to distinguish individuals on the basis of high and low 
parental monitoring level had relatively little impact on our findings. Evidence of an 
association between parental monitoring and ever use of cigarettes at age 16 years 
was again observed, although evidence for this was not as strong as that observed for 
the original cut-off. Those in the low parental monitoring category (comprising 55% 
of the sample) were more likely to have tried smoking by this age (unadjusted: OR = 
1.19, 95% CI 1.02, 1.38, p = 0.03; adjusted: OR = 1.26, 95% CI 1.08, 1.48, p = 
0.003). Strong evidence of an effect of parental monitoring on initial smoking 
trajectories was also observed (unadjusted: p = 0.006; adjusted: p = 0.002), although 
again the effects observed were not as strong as those observed for the original cut-
off. Those in the low monitoring category (again comprising 55% of the sample) 
were more likely to be late onset regular smokers (unadjusted: OR = 1.39, 95% CI 
1.07, 1.82; adjusted: OR = 1.46, 95% CI 1.11, 1.91), and early onset regular smokers 
(unadjusted: OR = 1.61, 95% CI 1.07, 2.42; adjusted: OR = 1.68, 95% CI 1.11, 2.56). 
Finally, as previously observed, no evidence of an interaction between parental 
monitoring and rs6265 and rs1051730 was noted for either initiation phenotype (ps > 
0.43). 
 
3.4 Discussion 
We used data from a prospectively assessed cohort to examine evidence for 
association between rs6265 (BDNF) and rs1051730 (CHRNA3) and smoking 
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initiation in adolescence, characterised using two distinct phenotypes: ever use of 
cigarettes, and initial smoking trajectories. We also sought to determine the potential 
influence of parental monitoring on these relationships. We found no clear evidence 
of an association between either genetic variant and either initiation phenotype, nor 
evidence of modification of genetic effect by parental monitoring in any instance. 
Strong evidence of an effect of parental monitoring on both initiation phenotypes 
was observed however. 
We found no evidence to suggest that rs6265 in BDNF was associated with 
smoking initiation. This variant was primarily included in this study as a positive 
control, given its recent association with smoking initiation  (Furberg et al., 2010). 
However, given the sample size of the current study, and the effect size (OR = 1.06)  
observed for rs6265 in the original meta-analysis, we did not have good power to 
detect an effect at this locus.  
Whilst our small sample size certainly limited our ability to detect very 
modest genetic effects, we felt that our more precise assessment of the initiation 
phenotype somewhat offset this issue. Our failure to note such an association in a 
prospectively assessed cohort calls into question the ‘initiation’ phenotype typically 
employed in genome-wide association studies. Issues relating to phenotype definition 
are discussed below, and in further detail in Chapter 4. 
We found strong evidence of an association between parental monitoring and 
smoking initiation, assessed both in terms of ever use, and initial smoking trajectory. 
Low parental monitoring was associated with an increased risk of smoking initiation. 
This finding complements previous research, which has shown that parental 
monitoring is a risk factor for substance use, including smoking (Bohnert et al., 
2009), and emphasises the need to target smoking prevention strategies at this at-risk 
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group, whilst simultaneously advising parents of the benefits of monitoring their 
children. 
 No clear evidence of an association was observed between rs1051730 and 
smoking initiation. This variant is known to influence receptor response to nicotine 
(Bierut et al., 2008), which should not plausibly effect very first use of cigarettes. 
However, one might expect this variant to be associated with behaviours after initial 
exposure to tobacco, such as risk of progression from experimentation to regular 
smoking, a pathway captured by our late- and early-onset regular smoker categories. 
Marginal evidence of an association between this variant was observed for initial 
smoking trajectories in adjusted analyses (p > 0.09) , although in the opposite 
direction to that predicted, with the T allele (previously associated with increased 
daily cigarette consumption and nicotine dependence) appearing marginally 
protective for late-onset and early-onset regular smoking. Reasons for this are 
unclear. Allele miscoding was ruled out following inspection of allele frequencies. It 
would certainly be of interest to examine data collected over a longer period into 
adulthood to capture the development of this influence, ideally combined with a 
larger sample size.  
 We found no evidence to suggest an influence of parental monitoring on the 
relationship between rs1051730 and either initiation phenotype. This finding 
conflicts somewhat with that of Chen et al. (2009), who observed that the association 
of rs16969968 with nicotine dependence was modified by level of parental 
monitoring. Although, unlike Chen et al. (2009), our study was not based on a 
selected sample, our sample was considerably larger (2687 and 3771  versus 2027 in 
the Chen et al. study). It is therefore unlikely that our failure to observe a similar 
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pattern of associations was merely due to low statistical power. One possibility is 
that the different phenotypes studied here may account for this disparity.  
This study has several strengths. The use of data from a prospectively 
assessed cohort ensured that we could be confident that we were truly measuring 
smoking initiation. Our use of initial smoking trajectories as a phenotype was also a 
strength, capturing the complexities of cigarette use during adolescence. This 
approach may provide richer data for analysis of genetic effects (Munafo & 
Johnstone, 2008). Characterisation of smoking initiation is normally vague, and 
certainly varies considerably between studies. Typically, ‘ever smokers’ are 
contrasted with ‘never smokers’ for the purposes of analyses (e.g., Caporaso et al., 
2009). Definitions of these two groups vary substantially however. Furberg et al. 
(2010) contrasted ever regular smokers versus never regular smokers in their 
examination of smoking initiation, regular smokers defined as “those who reported 
having smoked ≥100 cigarettes during their lifetime”, never regular smokers defined 
as “those who reported having smoked between 0 and 99 cigarettes during their 
lifetime”. In contrast, Greenbaum et al. (2006) compared never smokers (reporting 
never to have smoked a single cigarette in their lives, termed ‘noninitiators’) with 
individuals who had “smoked daily for at least 1 year” (termed ‘smoking initiators’). 
Such variation may potentially underlie persistent failures to replicate findings, and 
highlights the need for more narrowly defined phenotypes, as utilised here. Finally, 
consideration of important covariates in our analyses, including maternal smoking 
during pregnancy and level of maternal education, was an additional strength of this 
study. 
Several limitations should be acknowledged. Firstly, our parental monitoring 
measure relied solely on child self-report, and was assessed using a brief, three item 
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questionnaire. Ideally we would have also incorporated a parental report, but data on 
parental monitoring provided by the mothers of the individuals in this sample were 
not available at (or close to) the age of 11 years.  A more comprehensive assessment 
of parental monitoring developed from Stattin and Kerr’s monitoring measure was 
administered to both ALSPAC offspring and their mothers, the use of which would 
have enabled us to: a) examine effects of different dimensions of parenting practices 
on smoking initiation (an issue discussed further below), and b) incorporate both 
child and parent opinion on monitoring practices. However, these questionnaires 
were administered when the children were 14 years old, by which time a substantial 
number had already tried smoking. As such, use of these measures would have 
required substantial further restriction of our sample, given the necessity to exclude 
all individuals who had tried smoking before time of assessment.  Our results 
pertaining to level of parental monitoring and smoking initiation are consistent with 
previous research however, which somewhat negates these concerns. In addition, 
Laird et al. (2003) have previously observed that robust associations are noted 
between parental monitoring/knowledge and deviant behaviour regardless of whether 
either variable is assessed using parental or adolescent report. Secondly, it is 
important to note that parenting practices encompass a number of different 
dimensions. In this study we considered only one, namely parental monitoring, 
primarily focused on parental knowledge of the child’s peers and activities with such 
peers. In contrast, other studies in this field have considered the impact of multiple 
dimensions.  Chen, Storr, & Anthony (2005), for example, examined the impact of 
parental involvement/reinforcement and coercive parental discipline, alongside 
parental monitoring, on the risk of exposure to opportunities to try cannabis. Similar 
patterns of effects were observed for parental monitoring and parental 
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involvement/reinforcement, namely that low levels of monitoring and involvement 
were associated with earlier opportunities to try cannabis, and increased risk of said 
opportunities over the ten year period post assessment. Conversely, low levels of 
coercive discipline were associated with later opportunities to try cannabis, and 
decreased risk of said opportunities over the ten year period post assessment, relative 
to those exposed to higher levels of discipline. This illustrates the importance of 
considering different aspects of parenting practices.  Finally, an additional limitation 
of our study is that the smoking trajectories characterised did not perhaps capture the 
full development of smoking behaviours across adolescence. Consideration of 
smoking data across a broader age range (encompassing adolescence and early 
adulthood) would allow for a more valid examination of smoking trajectories. Such 
trajectories are currently being developed within ALSPAC, although were not 
available for use at the time of writing. 
Using data gathered from a prospectively assessed cohort, we examined 
evidence for association between rs6265 and rs1051730 and two precise 
measurements of smoking initiation. We also examined the impact of parental 
monitoring on these relationships. Whilst no evidence of association was observed 
for either genetic variant, or in support of gene-environment interplay, we do provide 
evidence to further underscore the importance of parental monitoring in late 
childhood in predicting risk of smoking initiation in adolescence. Secondly, we also 
illustrate the potential use of smoking trajectories as a phenotype for use in future 
examination of genetic effects. A collective move towards the use of such tightly 
characterised phenotypes may increase likelihood of effect replication. The 
importance of using more precise, well-defined phenotypes is illustrated and 
discussed further in the following chapters.
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Chapter 4 
Laboratory-based Techniques: 
CHRNA3, Cotinine and Smoking Topography 
4.1 Introduction 
 Carefully defined and well-characterised phenotypes offer greater 
measurement precision, conferring a cleaner genetic signal (through an increase in 
signal to noise ratio) and improving the likelihood of effect replication. Genome-
wide association studies have revealed an association between a locus in the nAChR 
gene cluster CHRNA5-A3-B4 and tobacco exposure, crudely defined in terms of self-
reported daily cigarette consumption (Furberg et al., 2010; Thorgeirsson et al., 2010). 
Consequent research has sought to refine this phenotype.  
 As discussed in Chapter 1, researchers have now begun to examine 
associations between the 15q locus and objective, precise measures of tobacco 
exposure, primarily levels of cotinine (the primary metabolite of nicotine) and other 
nicotine metabolites (Keskitalo et al., 2009; Le Marchand et al., 2008). These 
preliminary studies have indicated that the risk alleles for heaviness of smoking at 
this locus are also associated with cotinine levels, and that this association remains 
after adjustment for self-reported smoking. Munafò et al. (2012) sought to confirm 
this in a larger sample. Specifically they examined the association between 
rs1051730 and self-reported cigarette consumption alongside circulating levels of 
cotinine. Cotinine level was found to show a much stronger association with 
rs1051730 relative to self-reported cigarette consumption. Moreover, the association 
between this variant and cotinine was robust to adjustments made for self-reported 
daily cigarette consumption (see Figure 4.1), reducing the association by only 18%. 
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This suggests that even among equal cigarette consumers, there is genetically 
influenced variation in total nicotine exposure. Presumably this is due to differences 
in smoking topography, i.e., how a cigarette is smoked (number of puffs taken per 
cigarette, volume of smoke inhaled per puff, and so on). It is now well-established 
that smokers modify their smoking behaviour to self-titrate circulating nicotine to a 
level appropriate to their need (Strasser et al., 2007). Research using knock-out 
mouse models suggests that this locus influences self-titrated nicotine exposure via 
effects at receptors which influence toxicity of high doses nicotine (Fowler et al., 
2011).
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Figure 4.1. Meta-analysis of association of rs1051730/rs16969968 risk allele with 
cotinine levels in current smokers (reproduced with permission from Munafo et al., 
2012). 
  
 
Data from six independent studies contributed to the meta-analysis. In each study, 
linear regression was used to calculate per-allele association of rs1051730-
rs16969968 genotype with cotinine levels. Unadjusted and adjusted analyses are 
shown. Adjusting for daily cigarette consumption had minimal impact on the 
association. 
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 In collaboration with Nic Timpson (University of Bristol), I developed a 
protocol to determine potential mediation of the relationship between 
rs1051730/rs16969968 and cotinine levels by smoking topography. The results of 
such a study would determine whether the stronger association noted between this 
variant and cotinine (relative to daily cigarette consumption) is mediated via self-
regulated tobacco exposure. A full ethics application for this study was submitted to, 
and consequently approved by, the ALSPAC Ethics and Law Committee. 
Unfortunately, due to unavoidable and unexpected delays in participant invitation 
and circulation, combined with an extremely poor participant response rate of 0.3% 
(issues which are discussed at length in section 4.5), I was unable to conduct this 
study before submitting my thesis. Thus, my ability to address the research objective 
outlined above was prohibited. In the interim period however, I was able to pilot the 
procedure.  Here I present the results of the pilot study, conducted in the absence of 
genetic data and cotinine data, primarily intended to trial the general procedures and 
to determine the feasibility of including ‘roll-your-own’ tobacco smokers in the full 
study (given concerns regarding the compatibility of this type of cigarette with the 
smoking topography equipment). An additional, secondary aim was to examine 
trends in the relationships between self-reported and objectively assessed measures 
of tobacco exposure. Two methods sections are presented below. The first section 
presents the protocol for the full study, the second presents details specific to the 
pilot study.  
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4.2 Methods: Full study 
4.2.1 Experimental design 
 A recall-by-genotype design will be employed, whereby a genetic variant 
delivering functional change (in this case rs1051730/rs16969968) is used to select 
participants for extremely detailed, clinically relevant, phenotype examination. This 
approach maximises the power and information content of the sample whilst 
enabling collection of extremely precise phenotypic data impossible to collect in a 
much larger sample. 
4.2.2 Participants 
 A total of 200 participants will be recruited prospectively from the ALSPAC 
cohort of mothers on the basis of minor or major homozygote status at rs1051730 
(100 in each genotype group). All participants are to be current, daily smokers, in 
good physical health. Smoking status will be confirmed during initial screening by a 
carbon monoxide (CO) breath reading (CO breathalyser) and urinary cotinine 
assessment (yielding a positive or negative reading). Exclusion criteria will include 
current dependence on any substance other than nicotine and caffeine, and significant 
current or past physical illness. Pregnant and lactating women are also to be 
excluded. Participants will be reimbursed for their time with £50 worth of shopping 
vouchers on completion of the study. Full ethics approval for this study has been 
granted by the ALSPAC Ethics and Law Committee.  
4.2.3 Measures and materials 
 Smoking topography will be assessed using a smoking topography monitor 
(CReSS Pocket, Borgwaldt KC, Hamburg) (see Figure 4.2). This is a self-contained, 
battery-operated device, which measures ambulatory smoking behaviour, with time 
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and date tags assigned at cigarette insertion/removal, providing a highly quantitative 
view of cigarette smoking behaviour. Data captured include the following: puff 
volume; puff duration; puff flow; puffs per cigarette; inter-puff interval; time to first 
puff; time to removal; volume per cigarette. Onboard memory is used to store all 
measures. Smoking topography will be assessed both in the laboratory and in the 
participants’ ‘natural’ environment over the course of one day. Primary outcome 
measures will be total volume of tobacco smoke consumed per cigarette (ml) and per 
day (ml).The cigarette smoked in the laboratory is to serve several purposes. Firstly, 
it will allow participants the opportunity to become familiar with use of the monitor 
whilst assistance is available. Secondly, it will allow determination of the impact of a 
quantifiable tobacco dose on cardiovascular and affect measures. Examination of the 
impact of rs1051730 genotype on these responses may be explored in future research 
(see Section 5.4.2). 
 Cotinine levels are to be assessed from salivary samples. Saliva samples will 
be collected using salivettes (Sarstedt, Nümbrecht). Samples will be centrifuged 
twice (at 5800 rpm for 15 minutes) within 24 hours of collection to ensure removal 
of human tissue, frozen (at -30 ºC) and then sent to ABS Laboratories Ltd. for 
quantitative analysis of cotinine content.  
Genotyping has previously been undertaken by KBioscience Ltd. 
(www.kbioscience.co.uk), a company who use a proprietary competitive allele 
specific PCR system (KASPar) for SNP analysis. For this study we will focus on one 
SNP, namely rs1051730 (CHRNA3).  
 Questionnaires will be used to ascertain demographic information and 
information on smoking history. The Fagerström Test of Nicotine Dependence 
(FTND) (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) will be used to 
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determine level of nicotine dependence. The Brief Questionnaire of Smoking Urges 
(QSU-Brief) (Cox, Tiffany, & Christen, 2001; Tiffany & Drobes, 1991) and the 
Positive and Negative Affect Scale (PANAS) (Watson, Clark, & Tellegen, 1988) will 
be administered pre- and post-programmed cigarette smoking to assess craving and 
affect respectively. 
 Cardiovascular measures (blood pressure and heart rate) will be assessed 
using the OMRON M6 blood pressure monitor.
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Figure 4.2. Smoking topography monitor (CReSS Pocket, Borgwaldt KC, Hamburg). 
[This image has been removed by the author for copyright purposes] 
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4.2.4 Procedure 
 The study will take place over the course of three days (see Figure 4.3). On 
day one the participant will attend the research centre for approximately 45 minutes. 
An information sheet will be issued, and written, informed consent provided. 
Smoking status will be confirmed by a CO breathalyser reading (PiCO+ 
Smokerlyzer, Bedfont Scientific) and urinary cotinine assessment. A series of 
questionnaires will then be administered to establish participant demographic 
information, smoking history, and level of nicotine dependence. A saliva sample will 
then be collected for quantitative assessment of cotinine level. Participants will 
consequently be introduced to the smoking topography monitor, and issued with 
instructions regarding its use. Pre-cigarette PANAS and QSU-Brief questionnaires 
are to be completed, and cardiovascular measures assessed (blood pressure and heart 
rate). Participants will then be asked to smoke one of their own cigarettes using the 
smoking topography monitor. This will take place in a ventilated cubicle 
(conforming to requirements of the Health Act 2006), under observation by the 
investigator through one-way glass. The participant will be able to speak to the 
investigator via an intercom system at any point during the procedure. Post-cigarette 
PANAS and QSU-Brief questionnaires will then be completed, and cardiovascular 
measures again assessed. At the end of this session, the participant will be issued 
with a smoking topography monitor, alongside an information sheet regarding its use 
and care. On day two, participants will be asked to use the smoking topography 
monitor for each cigarette consumed that day in their ‘natural’ environment. On day 
three, participants will return to the research centre to return the device. 
Alternatively, if more convenient, the researcher will visit the participant’s home 
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address to collect this. Following completion of this second visit, participants will be 
reimbursed and a debrief sheet outlining the aims of the study will be issued.
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Figure 4.3. Study procedure.
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4.2.5 Statistical analysis 
 Potential mediation of the relationship between rs1051730 genotype and 
cotinine levels by primary smoking topography outcome measures will be examined. 
Specifically, cotinine level will be regressed on rs1051730 genotype, to confirm the 
previously observed relationship. Smoking topography outcome will then be 
regressed on rs1051730 genotype, to confirm that this variant is indeed a predictor of 
the mediator. Finally, we will confirm that smoking topography is a significant 
predictor of cotinine level whilst controlling for rs1051730 genotype.  
4.3 Methods: Pilot study 
4.3.1 Participants 
 Participants were recruited from the University of Bristol student body and 
the general public via circulated advertisements and word of mouth. All were current 
smokers (confirmed by breath CO reading and/or urinary cotinine assessment), and 
in good physical and psychiatric health. Exclusion criteria were identical to those 
outlined above. Participants were reimbursed for their time with £25 upon 
completion of the study. Full ethics approval for this study was granted by the 
Faculty of Science Human Research Ethics Committee at the University of Bristol. 
4.3.2 Measures and materials 
 As outlined above. Please note, however, that genetic data were not obtained 
from these individuals. Please also note that whilst salivary cotinine samples were 
obtained from individuals participating in the pilot study, quantitative analysis of 
cotinine content was not conducted (due to laboratory turn-around time combined 
with imminence of thesis submission deadline).   
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4.3.3 Procedure 
 As outlined above. Please note, however, that the second visit took place 
solely at the research centre for this pilot study. 
4.3.4 Statistical analysis 
 Exploratory analyses were conducted to examine associations between self-
reported daily cigarette consumption, FTND score, and smoking topography 
outcome measures, including actual daily cigarette consumption (Pearson 
correlation).  
4.4 Results  
4.4.1 Participant characteristics  
 Our sample consisted of nine participants, of whom five were male (56%) 
and four were female (44%). The sample was predominantly White (White: 89%; 
Asian: 11%). Average age was 26.6 years (range = 20 to 42; SD = 7.62). Participants 
consumed an average of 9.5 cigarettes per day (range = 1 to 20; SD = 6.66), as 
determined through self-report. Just over half of the sample primarily smoked 
manufactured cigarettes (56%), with a slightly smaller proportion reporting use of 
‘roll-up’ cigarettes (44%) as their primary form of tobacco. A number of participants 
reported smoking a mixture of both manufactured and ‘roll-up’ cigarettes. Mean 
nicotine content of cigarette was 0.66 mg (range = 0.5 to 0.9; SD = 0.22) (NB: these 
figures could only be calculated for smokers of manufactured cigarettes, as the 
nicotine content of roll-up cigarettes varies widely due to a number of variable 
parameters e.g., type of cigarette paper used, diameter of filter, and so on). Mean 
FTND score was 2.89 (range = 1 to 8; SD = 2.32), indicative of relatively low levels 
of nicotine dependence. Mean age of smoking initiation was 15.4 years (range = 13 
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to 21; SD = 2.95). Mean CO breath reading was 13.11 ppm (range = 3 to 33; SD = 
9.64). 
4.4.2 Smoking topography outcomes 
 Laboratory: Mean number of puffs taken on the cigarette smoked under 
observation in the laboratory was 15.3 (95% CI 13.5, 17.1; SD = 2.3). Mean puff 
volume was 44 ml (95% CI 32, 56; SD = 15.2). Over the course of this cigarette, 
participants inhaled a mean total volume of 671 ml (95% CI 482, 861; SD = 246.4) 
(see Table 4.1). For reference, these figures are analogous to those determined in a 
similar study conducted by Strasser et al. (2007). 
 Home: Over the course of one day, participants consumed an average of 7.6 
cigarettes (95% CI 4.5, 10.6; SD = 3.9). Mean total number of puffs over the course 
of one day was 97.4 (95% CI 60.8, 134.1; SD = 47.7), and mean total volume of 
smoke inhaled over the course of the day was 5159 ml (95% CI 2442, 7876; SD = 
3534.7) (see Table 4.1).  
 Per cigarette topography averages were also calculated from data collected at 
home. On average, participants took 13.1 puffs per cigarette (95% CI 12.2, 14.1; SD 
= 1.2), and mean volume of smoke inhaled per cigarette was 668 ml (95% CI 482, 
855; SD = 242.1). These values were comparable to those ascertained in the 
laboratory (see Table 4.1). 
4.4.3 Relationships between measures of tobacco exposure 
 Scatter plots illustrating relationships between measures of tobacco 
exposure/nicotine dependence are displayed in Figures 4.4 to 4.7. Evidence of an 
association between self-reported and objectively assessed daily cigarette 
consumption was observed (r = 0.74, p = 0.022; r
2
 = 0.55). Participants tended to 
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over-report daily cigarette consumption (although the difference between observed 
and self-reported mean values was not significant; p = 0.24).  
 Marginal evidence of an association was observed between self-reported 
daily cigarette consumption and total volume of smoke inhaled over the course of 
one day (r = 0.63; p = 0.069, r
2
 = 0.40). An association was also observed between 
objectively assessed daily cigarette consumption and total volume inhaled over the 
course of one day (r = 0.87, p = 0.002, r
2
 = 0.75). This second association was 
unsurprisingly stronger given that these two variables were both recorded on the 
same day.  
 Finally, marginal evidence of a correlation was observed between FTND 
score and total volume of smoke inhaled over the course of one day (r = 0.67, p = 
0.051, r
2
 = 0.45). Higher FTND scores were associated with larger daily inhalation 
volumes.
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Figure 4.4. Correlation between self-reported and objectively assessed daily cigarette 
consumption (r = 0.74, p = 0.022, r
2
 = 0.55). 
 
 
Figure 4.5. Correlation between self-reported daily cigarette consumption and total 
volume of smoke inhaled over course of day (r = 0.63, p = 0.069, r
2
 = 0.40). 
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Figure 4.6. Correlation between objectively assessed daily cigarette consumption and 
total volume of smoke inhaled over course of day (r = 0.87, p = 0.002, r
2
 = 0.75). 
 
 
Figure 4.7. Correlation between FTND score and total volume smoke inhaled over 
course of day (r = 0.67, p = 0.051, r
2
 = 0.45). 
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4.4.4 Impact of participant characteristics on smoking topography outcomes 
 Smoking topography outcome measures presented according to participant 
characteristics are displayed in Table 4.1. Analyses of differences in topography 
outcome measures between participant sub-groups were not conducted given 
extremely small cell counts which prohibited meaningful statistical assessment.  
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Table 4.1. Smoking topography outcome measures as a function of participant characteristics. 
Participant 
Characteristics 
 
Lab topography measures 
Home topography measures (average 
per cig) 
Home topography measures (total 
over day) 
 
n Number of puffs 
Total volume 
inhaled (ml) 
Mean number of 
puffs per cig 
Mean volume 
inhaled per cig (ml) 
Total number of 
puffs 
Total volume 
inhaled (ml) 
  M SD M SD M SD M SD M SD M SD 
Overall 9 15.3 2.4 672 246.4 13.1 1.3 669 242.1 97.4 47.7 5159 3534.7 
Sex              
   Male 5 15.2 3.0 569 210.2 13.4 1.4 646 271.0 106.8 43.5 5458 4021.3 
   Female 4 15.5 1.7 800 251.7 12.8 1.1 697 237.5 85.8 56.7 4784 3379.1 
Cigarette type              
   Manufactured 5 15.8 1.1 781 236.5 13.7 0.7 796 228.5 93.4 57.3 5727 4162.8 
   Roll-your-own 4 14.8 3.5 535 205.8 12.4 1.5 510 161.6 102.5 40.3 4448 3000.3 
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4.4.5 Cardiovascular and affective responses to cigarette smoking in laboratory 
 Positive affect decreased following cigarette consumption (p = 0.009). Mean 
change in positive affect (as determined by subtracting post-cigarette positive 
PANAS score from pre-cigarette positive PANAS score) was -3.4 (95% CI -5.8, -
1.1; SD = 3.0). There was no evidence of a change in negative affect as a 
consequence of cigarette smoking (p = 0.43). Mean change in negative affect (as 
determined by subtracting post-cigarette negative PANAS score from pre-cigarette 
negative PANAS score) was -0.6 (95% CI -2.1, 0.9, SD = 2.0).  
 Evidence of an increase across all cardiovascular measures was observed as a 
consequence of cigarette smoking (heart rate: p = 0.009; systolic blood pressure: p = 
0.062; diastolic blood pressure: p = 0.10). Mean increase in heart rate was 13.6 bpm 
(95% CI 4.5, 22.7; SD = 11.8), mean increase in systolic blood pressure was 7.7 
mmHg (95% CI -0.5, 15.8; SD = 10.6), and mean increase in diastolic blood pressure 
was 5.0 mmHg (95% CI -1.2, 11.2; SD = 8.1).  
4.5 Discussion 
 The primary aims of the pilot study  were to trial the study procedure and to 
determine the feasibility of including ‘roll-your-own’ tobacco smokers in the full 
study. A secondary aim was to examine relationships between self-reported and 
objectively assessed measures of tobacco exposure. These objectives were all 
successfully achieved, and, in relation to our secondary objective, we were able to 
illustrate the potential importance of using precise, objectively assessed phenotypes 
when considering tobacco exposure. 
 One important observation concerned the somewhat weak relationship 
observed between objectively assessed daily cigarette consumption and total volume 
of smoke inhaled over the course of one day. Only 75% of the variance noted in total 
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volume inhaled was accounted for by objectively assessed daily cigarette 
consumption. Participants who inhaled very similar volumes of smoke over the 
course of one day varied quite dramatically in daily cigarette consumption. This 
observation underlines the importance of using precise, objectively assessed 
measures of tobacco exposure.  
 Evidence of a relationship between self-reported daily cigarette consumption 
and objectively assessed daily cigarette consumption was observed. This relationship 
was not perfect, as predicted. Somewhat unexpectedly however, we found that 
participants tended to over-report their daily cigarette consumption, rather than 
under-report. It should be noted however that participants were advised not to use the 
monitor whilst driving, as this would present a safety hazard. As such, the number of 
cigarettes recorded on the device was likely to under-represent the actual number of 
cigarettes consumed over the course of a day. Indeed, upon completion of the study a 
number of participants reported consumption of at least one cigarette outside of the 
monitor over the course of the home testing day. This was attributed to driving, 
awkwardness of monitor use, and/or embarrassment of monitor use in public. In two 
instances the monitor battery died/monitor malfunctioned during the evening of the 
home testing day, which further contributed to this issue. Given the small effect sizes 
observed for genetic variants, it is imperative that we obtain information on every 
cigarette smoked by each participant for the full study. In light of the above, we will 
ensure that a new battery is inserted into each monitor each week. We will also stress 
the importance of using the monitor for every cigarette that is consumed on the home 
testing day. 
 The disparity noted between objectively assessed and self-reported daily 
cigarette consumption raises an interesting question. Which truly is a more accurate 
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assessment of heaviness of smoking? Theoretically, the objective assessment should 
be. However, this is of course dependent on the assumption that people do not 
change their smoking behaviour whilst using the topography monitor. As we have 
alluded to above, this does not necessarily hold true. We will be able to provide a 
more definitive answer to this question in our full study by comparing the 
relationship between cotinine level (a truly precise, objective assessment of tobacco 
exposure) and both objectively assessed and self-reported daily cigarette 
consumption. In either case, we have still illustrated that daily cigarette consumption, 
however it is assessed, does not account for all the variance noted in total volume of 
smoke inhaled over the course of a day. Clearly, in addition to the number of 
cigarettes consumed, the manner in which a cigarette is smoked (number of puffs, 
puff volume) is crucial here.   
 A primary aim of this pilot study was to determine the feasibility of including 
‘roll-your-own’ tobacco smokers in our full study. Smoking topography data 
acquired from roll-up tobacco smokers was somewhat messy. It became apparent 
from the raw topography data that individuals often had difficulty inserting roll-up 
cigarettes into the device successfully. This observation was verified by participant 
feedback upon completion of the study/return of monitor. Such difficulties were 
rarely observed for manufactured cigarette smokers. It was also apparent that use of 
the monitor was abandoned by roll-up tobacco smokers on occasion after multiple 
failed insertion attempts. As such, it appears necessary to exclude roll-your-own 
tobacco smokers from the full study. 
 Evidence of changes in cardiovascular and affect measures were observed 
following cigarette smoking in the laboratory. These figures are presented here solely 
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for completeness. In the full study, we shall examine the impact of rs1051730 
genotype on these responses.  
 This pilot proved useful for a number of reasons. It enabled us to trial the full 
study procedure, and also, perhaps most importantly, illustrated the importance of 
using precise, objectively assessed phenotypes when considering tobacco exposure 
assessment. This has key implications for epidemiology and genetic association 
studies, including large genome-wide association studies of smoking behaviour, 
which typically rely on retrospective self-report measures rather than precise, 
objective measures of tobacco exposure. As a consequence of this study we will 
make several amendments to our full study protocol, the most substantial of which 
entails the exclusion of ‘roll-your-own’ tobacco smokers. Minor amendments will 
also be made to case report forms and advice issued to participants concerning home 
use of the topography monitors. 
 In addition to piloting the protocol, great effort was also made to conduct the 
full study. Unfortunately, due to unavoidable delays in participant invitation 
circulation combined with an extremely poor participant response rate, I was unable 
to complete this. Following an extensive consultation process with the ALSPAC 
research team, 360 study invitations were sent to ALSPAC participants in early July 
2012. From this initial mail-out, a total of 26 responses were received (7.2%), of 
which only one was positive. This equates to a positive response rate of 0.3%. These 
figures stand in stark contrast to those of a similar recall-by-genotype study which 
was completed recently within the department. This study also entailed the 
recruitment of participants from the cohort of ALSPAC mothers. Of the 600 
invitations sent out for this study, 320 responses were received (53.3%), of which 28 
were negative. This equates to a positive response rate of 48.7%. The disparity in 
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response rate across these two studies may be attributable to a number of factors, 
perhaps the most major of which concerns the smoking factor. Individuals were not 
required to smoke in the study presented for comparative purposes, nor was smoking 
listed in the eligibility criteria. It is possible that individuals do not wish to explicitly 
hold their smoking habits and behaviours up for examination, particularly in light of 
the increasing social unacceptability of smoking. An alternative explanation for our 
poor response rate concerns the time period during which invitations were sent - it is 
possible that participant availability was poor over the summer months. Finally, it is 
of note that several ALSPAC sub-studies targeting ALSPAC mothers are currently 
running, and as such it is possible that this cohort is currently over-burdened.  
 In light of the difficulties encountered regarding participant recruitment, 
several amendments will be made to the recruitment process. Future invitation mail-
outs will be sent outside of holiday periods. Invitations will also be followed up with 
postcard reminders (and additional response forms) should no response have been 
received within two weeks of invite circulation. Furthermore, our target sample may 
also be widened to include the cohort of ALSPAC fathers (DNA samples are 
available for ~1000 partners).
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Chapter 5 
Genome-wide Association Study Meta-analysis: 
Association of Multiple Loci with Cotinine Levels in Daily Smokers 
5.1 Introduction 
 The advent of genome-wide technologies has greatly facilitated the search to 
determine which genetic factors contribute to specific diseases. Genome-wide 
association (GWA) studies conducted across multiple cohorts/studies (consortia), 
often featuring total sample sizes in excess of 50,000, are becoming increasingly 
common, with large sample sizes offering increased power to detect the small genetic 
effects common in complex behaviours such as smoking. Requiring no a priori 
hypotheses, these studies have proven successful in determining novel variants 
associated with disease (e.g., Furberg et al., 2010). However, these analyses typically 
employ relatively crude phenotypes (e.g., self-reported daily cigarette consumption), 
which is a necessity imposed by the need to harmonise phenotypic definitions across 
studies.  
 As previously discussed, objectively assessed phenotypes afford a ‘cleaner’ 
genetic signal, and maximise statistical power to detect genetic effects. This has 
previously been illustrated in relation to tobacco exposure phenotypes, through 
comparison of the association of rs1051730 (CHRNA3) with cotinine levels versus 
self-reported daily cigarette consumption (Keskitalo et al., 2009; Munafo et al., 
2012). Furthermore, the inadequacy of daily cigarette consumption as a proxy for 
total daily tobacco smoke exposure in current smokers was demonstrated in the 
previous chapter, focused on smoking topography. 
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 The goal of this chapter was to carry out a multi-centre meta-analysis of 
GWA data on cotinine levels in current, daily cigarette smokers, in order to identify 
genetic variants associated with level of tobacco exposure. This study design 
theoretically maximises statistical power to detect genetic effects, through 
application of a consortium based approach combined with use of a precise, 
objectively assessed phenotype.  
5.2 Methods 
5.2.1 Contributing studies 
 Seven studies (collectively forming the Cotinine Consortium) contributed to 
the GWA study meta-analysis: Multi-Ethnic Study of Atherosclerosis (MESA), 
Coronary Artery Risk Development in Young Adults (CARDIA), Framingham Heart 
Study, Finn Twin study, Health2000 GenMets study, TwinsUK, and Young Finns 
Study (YFS) (see Table 5.1). These seven samples resulted in a collective sample 
size of n = 2,139. The full consortium comprises four additional studies (ALSPAC, 
Netherlands Twin Registry, FinnRisk 2007, and KORA), although data from these 
studies were not available for analysis at the time of writing. 
5.2.2 Phenotype definition 
 Cotinine levels were determined from plasma, blood or urine samples, and 
quantified using immunoassay, radioimmunoassay or mass spectrometry. 
5.2.3 Sample inclusion criteria 
 Individuals within each sample were eligible for inclusion in analyses 
provided they were assessed for cotinine level at or after 17 years of age, were of 
European ancestry, were successfully genotyped genome-wide (>95%), and were 
current daily smokers at the time of cotinine assessment. To minimise inclusion of 
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non-smokers and non-daily smokers in our analyses, specific inclusion thresholds 
were imposed regarding cotinine level, which we determined on the basis of expert 
recommendation and ROC analyses. These were conservatively set at 10 ng/ml 
cotinine in serum/plasma samples assessed using mass spectrometry, 50 ng/ml 
cotinine in serum/plasma samples assessed using immunoassay, and 250 ng/ml 
cotinine in urine samples assessed using immunoassay. Full descriptive 
characteristics of each study participating in the Cotinine Consortium are presented 
in Table 5.1. 
5.2.4 Genotyping and imputation 
 All contributing studies performed their own genotyping, genotyping quality 
control, and imputation (see Table 5.2). Studies samples were genotyped on a 
number of different platforms. Each study applied its own set of quality control 
filters. Genotype imputation was performed using IMPUTE prior to GWA analyses, 
using 1000 Genomes (March 2012 release) as a reference, resulting in a common set 
of approximately nine million SNPs. Unfortunately, imputed data for three samples 
(CARDIA, MESA and Framingham) was unavailable at the time of writing. As such, 
only directly genotyped SNPs were included in the meta-analysis for these samples 
(~500,000). 
5.2.5 Study specific GWAS analysis 
 Prior to study specific GWA analyses, cotinine data were transformed if 
necessary to correct for positive skew (using natural logarithm or square-root), and 
then standardised (i.e., converted to Z-scores). An additive genetic model was used 
for association analyses. Linear regression was used in each instance, with 
standardised cotinine level as the dependent variable and allele dose (0, 1 or 2 copies 
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of the minor allele) as the independent variable. Two specific regression models were 
used: 
a) Cotinine = SNP + Sex 
b) Cotinine = SNP + Sex + Age 
 Where age data were not available (i.e., Framingham), analyses using 
regression model b) were not performed. For family-based studies (e.g., FinnTwin), 
only one observation per family was included.  
5.2.6 Meta-analysis of GWAS results 
 All GWA study data files were delivered to the University of Bristol via 
secure file-sharing services. Imputation quality control procedures were then 
centrally imposed. Specifically, variants were excluded if a) MAF <1%; and/or b) 
info score < 0.4 or r
2
 <0.3. Genomic control correction was applied to all input files 
prior to running the meta-analysis to correct for population structure. Once the 
quality of each data file was confirmed, files were imported into METAL (March 
2011 Release) (http://www.sph.umich.edu/csg/abecasis/metal/index.html), a software 
tool for meta-analysis of whole genome association data. A fixed-effects meta-
analysis was then performed for each SNP by combining allelic effects weighted by 
the inverse of their variance. Secondary correction for population structure via 
genomic control of summary statistics was also performed. The fixed threshold for 
genome-wide significance was set at p < 5 x 10
-8
.  
5.3 Results 
 Meta-analysis was completed for 9,736,614 variants. The genomic control 
parameter (λGC) for meta-analysis summary statistics was 0.998 so no further 
adjustments to these data were made. Seventy-one variants exceeded the threshold 
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for genome-wide significance, set at p < 5 x 10
-8
 (see Figure 5.1). The ten variants 
with the lowest p-values are displayed in Table 5.3. A QQ plot illustrating the 
significance of association of all SNPs in the meta-analysis versus that expected 
under the null hypothesis is displayed in Figure 5.2. 
   
 
Table 5.1. Descriptive characteristics of Cotinine Consortium studies contributing to the genome-wide meta-analysis. 
Study n Sex (% male) 
Age (years) Cotinine (ng/ml)1 
Medium Method 
Mean SD Mean SD 
MESA 207 58.7 59.9 9.1 4235.8 4142.5 Urine Immunoassay 
CARDIA 387 47.8 25.3 3.4 202.0 137.8 Plasma Radioimmunoassay 
Framingham 93 43.0 N/A N/A 101.3 55.6 Plasma/serum Mass spectrometry 
FinnTwin 145 46.2 23.0 1.5 206.6 107.5 Serum Mass spectrometry  
GenMets 485 57.84 47.3 11.2 490.1 250.6 Serum Immunoassay 
YFS 147 50.3 35.5 3.1 215.7 112.6 Serum Mass spectrometry  
TwinUK* 675 8.9 48.1 13.7 N/A N/A Plasma Unknown 
 
* No unit of measurement available for cotinine currently so unable to impose agreed cut-offs. Smoking status determined on the basis of self-
report data in this one instance. 
1
 Cotinine mean and SD refer to post-threshold, pre-transformation values.
   
 
Table 5.2 Genotyping, imputation and statistical analysis for contributing studies. 
 
Study 
Genotyping Imputation¹ 
Association analyses 
Platform 
Inclusion criteria SNPs met 
QC criteria 
Imputation 
software 
Inclusion criteria 
MAF 
Call 
rate 
P HWE MAF 
Imputation 
quality 
SNPs in meta-
analysis 
λGC 
MESA Affy 6.0 . >99% . 579,750 N/A N/A N/A 504,023² 1.006 
CARDIA Affy 6.0 . >99% . 720,483 N/A N/A N/A 592,178² 1.011 
Framingham Affy 5.0 . >99% . 500,571 N/A N/A N/A 431,492² 1.018 
FinnTwin* Illumina 670K >1% >95% >1x10-6 504,770+* IMPUTE ≥1% Info > 0.4 8,581,728 1.006 
GenMets Illumina 610K >1% >95% >1x10-6 555,388 IMPUTE ≥1% Info > 0.4 8,519,598 1.011 
YFS Illumina 670K ≥1% ≥95% >1x10-6 546,677 IMPUTE ≥1% Info > 0.4 8,460,465 1.009 
TwinUK Illumina 317K+610K ≥1% ≥95% >5x10-6 281,269 IMPUTE ≥1% Info > 0.4 8,392,702 1.012 
 
*This sample comprised three sub-samples, which contributed 549,060, 549,544, and 504,770 directly genotyped variants respectively. 
¹Imputation quality control imposed centrally at University of Bristol. 
² Directly genotyped SNPs with MAF <1% had not been excluded from these three studies. I excluded these variants before running the meta-
analysis, hence values in the ‘SNPs in meta-analysis’ column differ from those in the ‘SNPs met QC criteria’ column despite lack of imputation 
and therefore associated imputation QC procedures. 
   
 
Table 5.3 Top 10 SNPs associated with cotinine level in genome-wide meta-analysis. 
 
SNP Chromosome Gene Alleles BETA SE p Direction* 
rs192004622 3  T/G -10.539 1.4246 1.38E-13 ??????- 
rs10519203 15 AGPHD1 T/C -0.227 0.0323 2.10E-12 ------- 
rs951266 15 CHRNA5 T/C 0.2364 0.0337 2.20E-12 +?+++++ 
rs144638935 X  A/G -7.4124 1.0669 3.72E-12 ??????- 
rs55853698 15 CHRNA5 T/G -0.2504 0.038 4.25E-11 ???---- 
rs8034191 15 AGPHD1 T/C -0.2495 0.0379 4.64E-11 ???---- 
rs2036527 15  A/G 0.2499 0.038 4.90E-11 ???++++ 
rs72740955 15  T/C 0.2497 0.038 4.99E-11 ???++++ 
rs55781567 15 CHRNA5 C/G -0.2487 0.038 5.89E-11 ???---- 
rs931794 15 AGPHD1 A/G -0.2486 0.038 5.94E-11 ???---- 
 
*Refers to direction of effect. A ‘+’ indicates allele 1 is driving the effect, a ‘-‘ indicates allele 2 is driving the effect.
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Figure 5.1. Manhattan plot illustrating genome-wide association results for the 
Cotinine Consortium. 
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Figure 5.2 QQ plot illustrating significance of association of all SNPs in the genome-
wide meta-analysis versus that expected under the null hypothesis. 
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 Eight of our top ten SNPs are located within the 15q region on chromosome 
15 and are in strong LD with rs1051730, the variant which has formed the focus of 
this thesis. Our second top hit was rs10519203 with a p-value of 2.10 x 10
-12
. This 
variant, located in an intron region of AGPHD1, was genotyped and/or imputed 
successfully in all seven studies (for reference, info score > 0.98 in every instance), 
and the direction of the effect was consistent across studies (i.e., C allele associated 
with lower cotinine levels). AGPHD1, also known as LOC123688, encodes the 
aminoglycoside phosphotransferase domain containing 1 protein, and is adjacent to 
the CHRNA5-A3-B4 gene cluster on chromosome 15 (see Figure 5.3).  
 The  lowest p-value generated in our analyses was 1.38 x 10
-13
 at marker 
rs192004622. This variant is located in chromosome 3. However, this hit was driven 
solely by one sample (YFS), having not been genotyped or imputed successfully in 
the other six samples, and as such should be treated with scepticism. Of note, the info 
score for this SNP was 0.64, indicative of relatively poor imputation. Similarly, a 
variant on chromosome X (rs14463893) was also identified as one of our top ten hits. 
The association noted for this variant was however again driven solely by one study 
(YFS). The info score for this variant was 0.51, which is again relatively low and 
suggestive of poor imputation. 
 Of the remaining 61 variants which reached or exceeded the threshold for 
genome-wide significance, the vast majority were located in the 15q region of 
chromosome 15, as illustrated in Figure 5.3. A handful of variants were identified on 
other chromosomes (namely 1, 2, 3, 4, 6, 11, 13, 14, 16, 17 and 19), although in 
every instance the association was driven solely by one study, the variant having 
been unsuccessfully genotyped or imputed in the other six instances. One exception 
was a variant on chromosome 12, namely rs117376610 (p = 2.47 x 10
-8
). This SNP 
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was successfully genotyped and/or imputed in three studies, and the direction of 
effect was consistent across studies (i.e., A allele associated with higher cotinine 
levels). This variant is located within ANKS1B, a gene which encodes ankyrin repeat 
and sterile alpha motif domain containing 1B protein. A plot of this region is 
presented in Figure 5.4. 
   
 
Figure 5.3. Regional plot of associations with cotinine level on chromosome 15 determined from genome-wide meta-analysis. 
 
 
SNPs plotted by their position on chromosome 15 against –log10 p value for their association with cotinine level in genome-wide meta-analysis. 
Estimated recombination rates are plotted in pale blue to reflect local LD structure on secondary y axis. The reference SNP (rs10519203) is 
highlighted in purple. The SNPs surrounding this reference SNP are colour coded to reflect their LD with this variant (see legend). Genome build 
= hg19; LD population = 1000 Genomes March 2012 release (EUR). Image generated using LocusZoom (http://csg.sph.umich.edu/locuszoom/).
   
 
Figure 5.4. Regional plot of associations with cotinine level on chromosome 12 determined from genome-wide meta-analysis. 
 
SNPs plotted by their position on chromosome 12 against –log10 p value for their association with cotinine level in genome-wide meta-analysis. 
Estimated recombination rates are plotted in pale blue to reflect local LD structure on secondary y axis. The reference SNP (rs117376610) is 
highlighted in purple. The SNPs surrounding this reference SNP are colour coded to reflect their LD with this variant (see legend). Genome build 
= hg19; LD population = 1000 Genomes March 2012 release (EUR). Image generated using LocusZoom (http://csg.sph.umich.edu/locuszoom/).
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5.4 Discussion 
 We combined a consortium based approach to genome-wide association with 
use of a precise, objective phenotype, to identify genetic variants associated with 
level of tobacco exposure. We found strong evidence for an association between a 
number of variants within the 15q region in chromosome 15 and cotinine level, the 
majority of which were located in the CHRNA5-A3-B4 gene cluster and adjacent 
genes, including AGPHD1, and were in strong LD. Additionally, we also found 
promising evidence for an association with a novel locus in ANKS1B on chromosome 
12. 
 The majority of significant associations noted consisted of variants located in 
chromosome 15, a region robustly linked to a spectrum of tobacco use phenotypes. 
Our top hit in this region was rs10519203 in AGPHD1. This gene, also known as 
LOC123688, encodes the aminoglycoside phosphotransferase domain containing 1 
protein, and is adjacent to the CHRNA5-A3-B4 gene cluster on chromosome 15. The 
rs10519203 variant is in strong LD with rs1051730 (r
2
 = 0.93, 1000 Genomes CEU), 
and has previously been associated with nicotine dependence (Saccone, Wang et al., 
2009)  and lung cancer risk (Amos et al., 2010). Of note, five of our top ten hits in 
this region map perfectly onto those identified by Liu et al. (2010) in this region in a 
genome-wide meta-analysis of smoking quantity. This is encouraging given our 
sample size of ~2,000 compared to their much larger sample of ~40,000, and 
illustrates one of the benefits of using precise, objective phenotypes relative to cruder 
measures. The top hit identified in the 15q region by Liu et al. (2010) corresponded 
to the fifth top hit in our study, namely rs55853698. This variant is located within the 
5’ untranslated region of CHRNA5, and as such is a potential candidate for affecting 
mRNA transcription, as Liu et al. (2010) have previously reported. 
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 One promising, unexpected hit observed in this study was variant 
rs117376610, located in the intron region of ANKS1B. ANKS1B encodes a multi-
domain protein that is predominantly expressed in brain and testis. Interestingly, this 
gene has previously been found to associate with addiction phenotypes, including 
polysubstance use, alcohol dependence, and methamphetamine use (Liu et al., 2006; 
Uhl et al., 2008). Also of potential interest is that down-regulation of this gene has 
been noted in oral cancer tissues (Zain et al., 2010). However, to the best of our 
knowledge, this gene has not previously been associated with heaviness of smoking 
phenotypes.  
 It is of note that this chapter serves as an interim presentation of our results. 
To date, 11 studies (comprising 12 samples) have agreed to contribute to the 
Cotinine Consortium. Whilst GWA data have only been provided from seven studies 
thus far, the results of which are included here, we shortly expect to receive 
additional data from our remaining samples. Once data from all constituent studies 
have been received, alongside data relating to additional, imputed variants from the 
CARDIA, MESA and Framingham studies, we will re-run our meta-analysis. The 
increased combined sample size should theoretically afford additional power to 
detect further variants. It will also be of certain interest to see if the significant 
association in ANKS1B holds in this larger sample. Furthermore, we also plan to 
replicate our findings in an independent sample if possible. 
 In summary, using a genome-wide meta-analytic approach, we have found 
evidence for association between cotinine levels in current smokers and, on the one 
hand, the 15q region on chromosome 15 (a locus which has been found to robustly 
associate with tobacco exposure in previous studies), and on the other, a potential 
novel locus located in ANKS1B on chromosome 12. In addition, we have illustrated 
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how the use of precise, objective phenotypes in GWA studies allows for the 
replication of findings generated by studies with much larger sample sizes. We hope 
to identify additional, novel variants as the total sample size of the consortium 
expands.
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Chapter 6 
 
 
Discussion 
6.1 Summary of main findings 
6.1.1 Systematic review and meta-analysis (Chapter 2) 
The aim of this study was to evaluate the strength of evidence for the 
association between rs1051730 (CHRNA3) and rs16969968 (CHRNA5) and 
heaviness of smoking, assessed in terms of daily cigarette consumption. Secondary 
aims were to determine which (if either) of the two variants  provided a stronger 
genetic signal, test for the existence of small study bias, explore the impact of year of 
publication, and investigate the impact of ancestry and disease state as potential 
moderating variables. Meta-analysis indicated compelling evidence of an association 
between the rs1051730/rs16966968 variants and daily cigarette consumption, 
equivalent to a per allele effect of approximately one cigarette per day. Weak 
evidence of small study bias was observed, although adjustment for this had minimal 
effect on the overall effect estimate. No evidence of an association between effect 
size estimate and year of publication was observed. The genetic variant rs1051730 
was found to provide a stronger signal than rs16966968 in stratified analyses, 
although this difference was only qualitatively observed in the subset of samples 
which provided data on both variants. No other differences in effect sizes were 
observed between stratified groups. In short, the rs1051730/rs16969968 locus is 
unequivocally associated with smoking, although uncertainty remains with respect to 
both the mechanism underlying this association, and other phenotypes with which 
this variant might be associated.  
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6.1.2 Genetic epidemiology (Chapter 3) 
 The aim of this study was to examine the association between rs1051730 and 
smoking initiation in adolescence, characterised using two distinct phenotypes: ‘ever 
use’ of cigarettes, and initial smoking trajectories, the latter determined using 
repeated measures of smoking frequency. This was examined using data from a 
prospectively assessed cohort. The potential influence of parental monitoring on this 
relationship was also examined. No evidence for association between rs1051730 and 
either initiation phenotype was observed, nor any evidence for effect modification by 
parental monitoring. The predicted main effect of parental monitoring on smoking 
initiation was observed. In conclusion, rs1051730 does not appear to be strongly 
associated with smoking initiation, although the relatively small sample size limited 
ability to detect modest genetic effects. While parental monitoring is strongly 
associated with smoking initiation, it does not appear to modify any association 
between rs1051730 and initiation, although this conclusion is limited by the failure to 
observe a main effect of this genotype.  
6.1.3 Laboratory-based techniques (Chapter 4) 
 The objective of this section was to  examine potential mediation of the 
relationship between rs1051730/rs16969968 and cotinine levels by smoking 
topography. The results of such a study would determine whether the stronger 
association noted between this variant and cotinine (relative to daily cigarette 
consumption) is mediated via self-regulated tobacco exposure. Due to unavoidable 
and unexpected delays in participant invitation, combined with an extremely poor 
response rate, I was unable to conduct this study.  A pilot study was however 
completed, conducted in the absence of genetic data and cotinine data, primarily 
intended to trial the protocol procedures, and to examine associations between both 
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objectively assessed and self-reported measures of tobacco exposure. The viability of 
including ‘roll-your-own’ tobacco smokers in the full study was also assessed. This 
pilot served as a useful feasibility study. It also, perhaps most importantly, illustrated 
the importance of using precise, objectively assessed phenotypes when considering 
tobacco exposure assessment. This has key implications for epidemiology and 
genetic association studies, including large genome-wide association studies of 
smoking behaviour, which typically rely on retrospective self-report measures rather 
than precise, objective measures of tobacco exposure. 
6.1.4 Genome-wide meta-analysis (Chapter 5)  
 The primary objective of this project was to identify genetic variants robustly 
associated with heaviness of smoking, in this instance assessed in terms of cotinine 
level, which, as has previously been demonstrated, is a more precise and objective 
assessment of tobacco exposure relative to self-reported daily cigarette consumption, 
thus offering a ‘cleaner’ genetic signal, and maximising power to detect genetic 
effects. To this end, we created a consortium (‘Cotinine Consortium’) comprised of 
seven studies to conduct a genome-wide meta-analysis of this phenotype.  As 
expected, we found strong evidence for an association between a number of variants 
within the 15q region in chromosome 15 and cotinine level, the majority of which 
were located in the CHRNA5-A3-B4 gene cluster and adjacent genes, including 
AGPHD1, and were in strong LD. Additionally, we also found promising evidence 
for an association with a novel locus in ANKS1B on chromosome 12. From a 
methodological perspective, we also illustrated how the use of precise, objective 
phenotypes in GWA studies allows for the replication of findings generated by 
studies with much larger sample sizes, and also potential allows for the identification 
of additional, novel variants. 
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6.2 Research implications 
 The robust association we, and others, have demonstrated between rs1051730 
and heaviness of smoking has definite practical implications for future research. 
Given said association, rs1051730 is well-suited to serve as an instrumental variable 
in Mendelian randomisation studies (see Davey Smith & Ebrahim, 2003), in this 
instance allowing the investigation of causal links between tobacco smoking and a 
variety of outcomes. Its utility in this context has previously been demonstrated (e.g., 
Freathy et al., 2011), and will be extended upon during the fellowship I have recently 
been awarded (Oak Foundation), in which I will be investigating causal links 
between tobacco use and a variety of health outcomes (including anxiety and 
depression). 
 The pilot smoking topography study demonstrated the superiority of precise, 
objectively assessed tobacco exposure phenotypes (i.e., inhalation volumes) over the 
more traditionally utilised phenotypes such as daily cigarette consumption (self-
reported or objectively assessed). Perhaps the most pertinent illustration of this was 
the observation that individuals who inhaled the same volume of smoke over the 
course of one day ranged widely in terms of daily cigarette consumption. This has 
key implications for epidemiology and genetic association studies, including large 
genome-wide association studies of smoking behaviour, which typically rely on 
retrospective self-report measures rather than more precise, objective measures of 
tobacco exposure. Our consequent adoption and application of this approach to the 
GWA field further illustrated the benefits of using precise, objective phenotypes 
relative to cruder measures. 
 On a related note, the genetic epidemiological study presented in Chapter 3 
illustrated the potential use of smoking trajectories as a phenotype for use in future 
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genetic association studies. A collective move towards the use of such tightly 
characterised phenotypes may increase the likelihood of effect replication. This 
statement should however be considered alongside the counter argument that simple 
phenotypes (with fewer assessment points and no requirement for data imputation 
and complex statistics) are easier to replicate than those that are complex. 
Simultaneously, if a genetic variant influences a ‘top-level’ phenotype (e.g., ever 
smoking) through multiple pathways, then the dissection and analysis of sub-level 
phenotypes is unlikely to lead to effect replication (given even smaller genetic effect 
sizes). 
6.3 Limitations  
 Minor limitations relating to each of the studies included in this thesis have 
been acknowledged and discussed in the preceding experimental chapters. This 
section focuses on the major limitations of each of these studies, alongside much 
broader limitations inherent to these fields of study, which impact both the studies 
included in this thesis and the wider literature. 
 Meta-analysis (Chapter 2): The primary limitation of the meta-analysis was 
that I did not have the data necessary to perform a joint SNP analysis of rs1051730 
and rs16969968, in which the effects of one variant were conditioned on the other. 
This analysis would have enabled me to comment more authoritatively on the 
difference in genetic signal between these two variants, if any, which are known to 
be in linkage disequilibrium. In addition, the focus of this study centred on what is 
essentially one genetic signal, whereas we now know that there are several 
independent signals within this region, all contributing to a proportion of phenotypic 
variance (for example, see Liu et al., 2010). 
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 Genetic epidemiology (Chapter 3): No evidence of an association was 
observed between rs6265 in BDNF and smoking initiation. This variant was included 
as a positive control, and its failure does somewhat limit the conclusions that can be 
drawn regarding observations for rs1051730.  The sample upon which this genetic 
epidemiological study was based was relatively small, thus limiting ability to detect 
very modest effects, such as that identified between rs6265 and smoking initiation by 
Furberg et al. (2010). Unfortunately there was little we could do to avoid this given 
sample attrition over time (an issue common to longitudinal studies) and variable 
requirements. A potential solution to this problem would involve combining 
ALSPAC data with comparable data from an additional birth cohort study, a larger 
sample offering increased power to detect such effects (see section 6.4.1). That said, 
we felt that our assessment of the initiation phenotype, which was much more precise 
than that typically employed in large GWA studies, somewhat offset this issue. 
 Laboratory-based techniques (Chapter 4): Unavoidable delays in participant 
invitation circulation combined with an extremely poor participant response rate 
precluded completion of the full planned recall-by-genotype smoking behaviour 
study. Unfortunately this prohibited examination of, or ability to comment on, 
potential mediation of the relationship between rs1051730 genotype and cotinine 
level by smoking topography measures. However, a full trial of the protocol was 
conducted, which illustrated an important point concerning precision of smoking-
related phenotypes. We were unable to comment conclusively on the superiority of 
objectively assessed daily cigarette consumption over consumption determined 
through self-report however in the absence of cotinine data. This will be examined in 
the full study which will be conducted during my fellowship. 
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 Genome-wide meta-analysis (Chapter 5): There were no major limitations to 
report in relation to this study. Whilst the combined sample size employed was 
relatively small for a genome-wide meta-analytic approach, our findings were almost 
wholly analogous to those identified in studies twenty times the size. This boldly 
illustrates one of the benefits of using precise, objective phenotypes relative to cruder 
measures. 
6.4 Future directions 
6.4.1 Genetic association studies  
Progress in the identification of genetic variants robustly associated with 
smoking-related phenotypes has been limited (the CHRNA5-A3-B4 locus is a rare 
exception). This is perhaps unsurprising given that the effects attributable to specific 
genetic variants tend to be very small in complex behaviours such as smoking. Use 
of crudely defined phenotypes, typically based on self-report, further confounds this 
issue. Future studies should seek to use much larger, consortia-based samples, 
maximising statistical power to detect effects, ideally combined with precisely 
defined, objective phenotypes, which offer a ‘cleaner’ genetic signal, an approach 
exemplified in Chapter 5. In addition, replication of studies should be positively 
encouraged. These studies should be adequately powered, rather than simply 
reflecting the size of the original ‘discovery’ study sample. Submission and 
publication of null findings (from adequately powered studies) should be 
encouraged, in relation to both novel studies, and replications.  
6.4.2 Recall-by-genotype studies 
 Recall-by-genotype studies involve the selection of participants on the basis 
of genotype at a specific locus delivering functional change. This approach 
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maximises the power and information content of the sample whilst enabling 
collection of extremely precise phenotypic data impossible to collect in a much 
larger sample, which may assist in the identification of potential mechanisms 
underlying genetic associations. The first logical extension of this thesis involves 
completion of the planned recall-by-genotype smoking topography study, examining 
potential mediation of the relationship between rs1051730 genotype and cotinine 
level by smoking topography measures.  
In a similar vein, it would also be of interest to examine the association 
between this locus and objectively assessed responses to nicotine challenge, again 
utilising a recall-by-genotype based approach. As discussed, research using knock-
out mouse models suggests that this locus influences self-titrated nicotine exposure 
via effects at receptors which influence toxicity of high doses of nicotine, particularly 
those localised to the medial habenula - interpeduncular nucleus pathway (Fowler et 
al., 2011). Translational research seeking to evaluate the effect of nicotine challenge 
on brain activation as a function of rs16969968 genotype using neuroimaging 
technologies is now called for, which may point to new targets for novel smoking 
cessation therapies. Additional laboratory based techniques/measures which could be 
used to investigate this aim include cardiovascular measures, galvanic skin response, 
and questionnaire batteries, administered pre- and post-administration of nicotine.  
6.4.3 Phenotype refinement 
 The methods developed and employed within this thesis, focused on careful 
refinement of phenotype, hold the potential for wider application. They could, for 
example, be extended to examine cannabis use. Loci robustly associated with 
cannabis use and dependence have yet to be identified. It is likely, however, that the 
effects we will observe between genetic variants and cannabis use will operate in a 
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similar manner to those observed for tobacco. If this is the case, then precise, 
objective measures of cannabis use (e.g., circulating metabolite levels of 
tetrahydrocannabinol and/or cannabindiol) may improve the success of GWA studies 
in identifying variants associated with cannabis use. Firstly, however, we would need 
to establish whether or not cannabis smoking is plastic in a similar way to tobacco 
smoking (as illustrated by Strasser et al., 2007). Specifically, we would need to 
examine whether cannabis smokers modify their smoking behaviour to self-titrate 
psychoactive components of cannabis to a level appropriate to their need. Precise 
dissection of this phenotype would be of certain benefit to large GWA studies 
seeking to determine variants associated with cannabis use. 
6.4.4 Clinical applications 
 From a clinical perspective, the ultimate goal of this line of research is to 
improve the efficacy of smoking cessation treatment. This may be accomplished via 
two avenues: 1) identification of novel treatment targets; and 2) genetic tailoring of 
existing pharmacotherapies (‘personalised medicine’). In this section we discuss how 
our research, alongside other relevant advancements in the field, has contributed 
towards these goals. 
Novel treatment targets: A robust association between the genetic variant 
rs1051730/rs16969968 and heaviness of smoking is now firmly established, as we 
and a number of other groups have demonstrated (e.g., Furberg et al., 2010; Ware, 
van den Bree, & Munafo, 2011). Perhaps counter to the usual route of scientific 
inquiry, these exciting findings, based exclusively on human samples and 
strengthened by their identification through agnostic genome-wide methods, have led 
to preclinical research focused on determining the mechanism underlying these 
associations. Exciting progress has been made using knockout mouse models, 
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highlighting the importance of α5 nAChR subunits in regulating nicotine intake, 
particularly those localised to the MHb-IPN pathway. Translational research seeking 
to evaluate the effect of nicotine challenge on brain activation as a function of 
rs16969968 genotype using neuroimaging technologies is now called for, which may 
point to new targets for novel smoking cessation therapies. It is possible, for 
example, that pharmacological stimulation of the MHb-IPN tract may act to 
reduce/limit nicotine intake/tobacco use. 
Personalised medicine: Given the robust association noted between the 15q 
locus and heaviness of smoking, one might speculate that individuals carrying the 
rs1051730/rs16969968 risk variant would benefit from an increased dose of nicotine 
replacement therapy (NRT) relative to non-carriers (to assist quit attempts). It is 
important to note, however, that the locus in question only accounts for a very small 
proportion of variance in this phenotype, and, over and beyond this, it may well be as 
effective to universally increase NRT dose, regardless of genotype. This latter option 
may certainly prove more economical. There is, however, a substantial genetic 
component to nicotine dependence (~.50). Therefore, the development of genetic risk 
scores based on multiple genetic variants (accounting for a much larger proportion of 
variance in heaviness of smoking) may hold more promise with regards to 
implementing such an approach.  
To date, the major pharmacogenetic success stories have come about for 
treatments with severe and unpleasant side effect profiles (e.g., chemotherapy 
treatments). As such, a pharmacogenetic approach to smoking cessation is perhaps 
most likely to be productive in identifying people who can tolerate second-line 
treatments (e.g., clonadine), which, whilst effective, aren’t widely used due to high 
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incidence of adverse effects such as sedation and nausea (Gourlay, Stead, & 
Benowitz, 2004). 
 As an aside, it is important to consider whether or not genetic tailoring of 
medication may prove to be cost-effective in relation to universal treatment in the 
field of smoking cessation. This has certainly been called into question (Ware & 
Munafo, 2012). Moreover, should this approach eventually prove more economical 
and effective than ‘broad-stroke’ medicine, we are still faced with important ethical 
issues and questions regarding the practicality of clinical implementation. The 
potential for discrimination (by employers and health insurers) on the basis of 
genetic information is certainly a key ethical concern (Shields, Lerman, & Sullivan, 
2004).  From a more practical standpoint, it is also important to consider the ability 
of health care providers to relay such information. Are general practitioners and other 
front-line clinicians sufficiently knowledgeable and adequately trained to provide 
information to patients regarding genetically tailored treatment options? And are they 
able to provide genetic counselling? An appropriate level of understanding 
(alongside availability of time and resources) will be required of clinicians delivering 
such information. These issues are discussed at length in Shields et al. (2004). The 
genetic literacy of the general public is also to be considered, and there is certainly a 
call for quantitative and qualitative research examining patient response to 
genetically tailored treatment. This is an area which is beginning to make progress 
(BEACON trial, Stanford University; 
http://clinicaltrials.gov/ct2/show/NCT00991081). We must also question the 
potential for the application of pharmacogenetic treatment approaches in the 
resource-limited developing world, where prevalence of tobacco use is increasing 
(WHO, 2008). 
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6.5 Conclusions 
 The primary aim of this thesis was to determine the role played by the 
CHRNA5-A3-B4 gene cluster in smoking-related behaviours, with an emphasis on 
phenotype refinement to aid understanding of the mechanisms underlying these 
associations. A number of different approaches were utilised to address this 
objective, namely systematic review and meta-analysis, genetic epidemiology 
(including detailed phenotyping of smoking behaviour in adolescence), laboratory-
based techniques, and genome-wide meta-analysis.  
 We found compelling evidence for a small, robust association between the 
rs1051730/rs16966968 variants and daily cigarette consumption, equivalent to a per 
allele effect of approximately one cigarette per day. This effect was consistent across 
population sub-groups. Compelling evidence for an association between this locus 
and level of tobacco exposure was further illustrated through genome-wide meta-
analysis of cotinine levels in current smokers. No association was observed between 
this locus and smoking initiation however, as examined in a prospectively assessed 
cohort using precisely defined phenotypes, although this observation should be 
viewed tentatively in light of the failure of our positive control. An association 
between rs1051730/rs16969968 and smoking topography has yet to be reported. 
However, a full protocol was developed and piloted to investigate this. In addition, 
we have also illustrated the importance of precise, objective, phenotype definition, an 
observation which has important implications for the fields of molecular genetics and 
epidemiology. 
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